EVIO (EVIO) 10-Q 18 Oct 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2019	Oct. 14, 2019
Document And Entity Information
Entity Registrant Name	EVIO, INC.
Entity Central Index Key	0000715788
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,288,776
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Current assets:
Cash and cash equivalents	$ 47,261	$ 81,736
Accounts receivable, net of allowance of $445,887 and $414,475	122,783	234,178
Prepaid expenses	131,982	45,940
Other current assets	113,694	146,816
Note receivable, current portion	100,000	100,000
Total current assets	515,720	608,670
Right of use assets	2,667,715
Capital assets, net of accumulated depreciation of $229,343 and $123,854	1,057,748	411,241
Assets not in service		455,540
Land	212,550	212,550
Property and equipment, net of accumulated depreciation of $897,746 and $520,437	3,623,541	3,525,772
Security deposits	160,353	159,632
Note receivable	1,200,000	1,200,000
Prepaid expenses	120,108	63,582
Intangible assets, net of accumulated amortization of $506,944 and $318,816	1,463,217	1,680,569
Goodwill	5,954,207	6,037,404
Total assets	16,975,159	14,354,960
Current liabilities:
Accounts payable and accrued liabilities	2,724,222	1,546,617
Client deposits	206,686	363,211
Interest payable	767,524	416,459
Capital lease obligation, current	865,558	677,030
Derivative liability	2,102,387	11,812,781
Convertible notes payable, net of discounts of $792,040 and $753,557, respectively	2,978,319	1,678,265
Loans payable, current, net of discounts $0 and $119,000, respectively	786,727	643,927
Total current liabilities	10,431,423	6,506,787
Convertible debentures, net of discounts of $3,484,269 and $4,043,836, respectively	1,698,731	1,153,164
Lease liabilities	2,716,047
Capital lease obligation, net of current	173,854	148,433
Loans payable, net of current	651,365	1,193,781
Convertible loans payable, related party, net of current		61,263
Loans payable, related party, net of current and discounts of $39,302 and $51,971	1,588,904	1,348,793
Total liabilities	17,260,324	10,412,221
Stockholders' Equity:
Common stock, $0.0001 par value. 1,000,000,000 authorized; 27,094,744 and 23,255,409 shares issued and outstanding at March 31, 2019 and September 30, 2018	2,709	2,326
Subscription Receivable	(406,000)
Additional paid-in capital	24,278,682	21,495,621
Retained earnings (accumulated deficit)	(25,554,846)	(19,226,462)
Accumulated other comprehensive income	(379,546)	(263,985)
Total stockholders' equity	(2,058,416)	2,008,105
Noncontrolling interest	1,773,251	1,934,634
Total equity	(285,165)	3,942,739
Total liabilities and stockholders' equity	16,975,159	14,354,960
Series B Preferred Stock [Member]
Stockholders' Equity:
Preferred stock	500	500
Total equity	500	500
Series C Preferred Stock [Member]
Stockholders' Equity:
Preferred stock	50	50
Total equity	50	50
Series D Preferred Stock [Member]
Stockholders' Equity:
Preferred stock	35	55
Total equity	$ 35	$ 55

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Allowance for accounts receivable	$ 445,887	$ 414,475
Accumulated depreciation of capital assets	229,343	123,854
Accumulated depreciation of property and equipment	897,746	520,437
Accumulated amortization of intangible assets	506,944	318,816
Discounts on convertible notes payable	792,040	753,557
Discounts on loans payable	0	119,000
Discounts on convertible debentures	3,484,269	4,043,836
Discounts on loans payable related party	$ 39,302	$ 51,971
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	27,094,744	23,255,409
Common stock, shares outstanding	27,094,744	23,255,409
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	5,000,000	5,000,000
Preferred stock, shares outstanding	5,000,000	5,000,000
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	500,000	500,000
Preferred stock, shares outstanding	500,000	500,000
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	349,500	552,500
Preferred stock, shares outstanding	349,500	552,500

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Revenues
Total revenues	$ 735,179	$ 732,311	$ 1,922,417	$ 1,679,176
Cost of revenue
Depreciation and amortization	321,846	55,706	612,304	84,819
Total cost of revenue	1,157,042	798,388	2,461,470	1,534,651
Gross margin	(421,863)	(66,077)	(539,053)	144,525
Operating expenses:
Selling, general and administrative	1,223,662	2,213,094	2,702,302	3,033,369
Depreciation and amortization	57,116	83,769	115,982	141,156
Total operating expenses	1,280,778	2,296,863	2,836,284	3,174,525
Income (loss) from operations	(1,702,641)	(2,362,940)	(3,375,337)	(3,030,000)
Other income (expense)
Interest income (expense), net	(692,419)	(1,102,537)	(2,457,297)	(1,387,188)
Other income (expense)	(33,422)		(97,517)
Gain (loss) on settlement of debt				(56,093)
Gain (loss) on change in fair market value of derivative liabilities	(1,409,305)	1,780,769	(556,647)	1,794,091
Total other income (expense)	(2,135,146)	678,232	(3,111,461)	350,810
Income (loss) before income taxes	(3,837,787)	(1,684,708)	(6,486,798)	(2,679,190)
Provision for income taxes (benefit)	613		2,969
Net income (loss)	(3,838,400)	(1,684,708)	(6,489,767)	(2,679,190)
Net income (loss) attributable to noncontrolling interest	18,439	(4,906)	(161,383)	(12,796)
Net income (loss) attributable to EVIO, Inc. shareholders	$ (3,856,839)	$ (1,679,802)	$ (6,328,384)	$ (2,666,394)
Basic and diluted earnings (loss) per common share	$ (0.16)	$ (0.11)	$ (0.25)	$ (0.20)
Weighted-average number of common shares outstanding: Basic and diluted	24,753,819	15,387,039	25,366,021	13,519,957
Comprehensive loss:
Net income (loss)	$ (3,838,400)	$ (1,684,708)	$ (6,489,767)	$ (2,679,190)
Foreign currency translation adjustment	(115,561)		(115,561)
Comprehensive income (loss)	(3,953,961)	(1,684,708)	(6,605,328)	(2,679,190)
Testing [Member]
Revenues
Total revenues	735,179	689,011	1,922,417	1,576,360
Cost of revenue
Cost of revenue for services	835,186	664,182	1,849,166	1,360,840
Consulting [Member]
Revenues
Total revenues		43,300		102,816
Cost of revenue
Cost of revenue for services		$ 78,500		$ 88,992

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018
Cash flows from operating activities of continuing operations:
Net income (loss)	$ (3,838,400)	$ (2,651,397)	$ (1,684,708)	$ (994,482)	$ (6,489,767)	$ (2,679,190)
Amortization of debt discount					1,951,983	1,199,159
Common stock issued in exchange for fees and services					240,501	254,720
Depreciation and amortization	57,116		83,769		115,982	141,156
Loss on disposal of assets					64,095
Loss on settlement of accounts payable						3,750
Loss on settlement of debt						56,093
Provision for doubtful accounts					35,333	3,067
Stock based compensation					395,850	1,234,415
Unrealized (gain) loss on derivative liability					556,647	(1,794,091)
Changes in operating assets and liabilities:
Accounts receivable					74,625	16,067
Prepaid expenses					(142,911)	77,954
Other current assets					33,122	(52,647)
Security deposits					(722)	(451,323)
Operating lease right of use assets					48,332
Accounts payable and accrued liabilities					1,179,775	(348,073)
Customer deposits and deferred revenues					(156,363)	(83,385)
Interest payable					410,712	192,616
Net cash provided by (used in) operating activities					(1,078,049)	(2,148,643)
Cash flows from investing activities:
Cash consideration for acquisition of business						20,468
Notes receivable						(39,987)
Deposit, related party						(200,000)
Purchase of fixed assets					(580,075)	(571,501)
Net cash provided by (used in) investing activities					(580,075)	(791,020)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs					186,000	508,000
Proceeds from issuance of convertible debentures					414,183	6,136,120
Proceeds from issuance of convertible notes, net of issuance costs					971,014
Proceeds from related party advances					199,040
Repayments of capital leases					(93,050)	(22,347)
Repayments of loans payable					(18,617)	(605,348)
Repayments of related party loans payable					(27,151)	(176,528)
Net cash provided by (used in) financing activities					1,631,419	5,839,897
Effect of exchange rates on cash and cash equivalents					(7,769)
Net increase (decrease) in cash and cash equivalents					(34,474)	2,900,234
Cash and cash equivalents at beginning of period		$ 81,735		121,013	81,735	121,013	$ 121,013
Cash and cash equivalents at end of period	$ 47,261		3,021,247		47,261	3,021,247	$ 81,735
Supplemental disclosure of cash flow information:
Cash paid for interest						80,028
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Conversion of convertible note and accrued interest into common stock					708,089	730,485
Reclassification of derivative liability to additional paid in capital			$ 601,139	$ 281,315		882,454
Settlement of account payable for common stock						18,750
Common stock issued for settlement of note payable						162,000
Common stock issued for settlement of related party note payable						62,500
Common stock issued for subscription receivable					406,000
Conversion of Series D Preferred stock to common stock						70
Debt discount recorded on convertible notes and debentures payable upon initial measurement of derivative liability					364,462	5,505,131
Debt discounts recorded for original issue discounts on convertible debentures					846,985	446,800
Equipment financed through capital leases					323,411	385,208
Issuance of convertible notes payable and other obligations in connection with the acquisition of a business						600,000
Sale and assumption of note payable and accrued interest					$ 556,658

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Common Stock [Member]	Stock Subscriptions Receivable [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Stockholders' Equity [Member]	Noncontrolling Interest [Member]	Total
Beginning Balance at Sep. 30, 2017	$ 500	$ 50	$ 83	$ 1,073		$ 7,657,982	$ (7,592,371)		$ 67,317	$ 158,124	$ 225,441
Beginning Balance, shares at Sep. 30, 2017	5,000,000	500,000	832,500	10,732,922
Net income (loss)							(986,592)		(986,592)	(7,890)	(994,482)
Change in foreign currency translation
Issuance of common stock in connection with the conversion of Series D preferred stock			$ (9)	$ 22		(13)
Issuance of common stock in connection with the conversion of Series D preferred stock, shares			(87,728)	219,320
Issuance of common stock in connection with sales made under private offerings				$ 125		497,875			498,000		498,000
Issuance of common stock in connection with sales made under private offerings, shares				1,245,000
Issuance of common stock in connection with the exercise of common stock purchase warrants
Issuance of common stock in connection with the exercise of common stock purchase warrants, shares
Issuance of common stock as compensation to employees, officers and/or directors				$ 2		6,562			6,564		6,564
Issuance of common stock as compensation to employees, officers and/or directors, shares				15,000
Issuance of common stock in exchange for consulting, professional and other services provided				$ 24		241,133			241,157		241,157
Issuance of common stock in exchange for consulting, professional and other services provided, shares				239,750
Issuance of common stock in connection with the settlement of accounts payable				$ 4		18,746			18,750		18,750
Issuance of common stock in connection with the settlement of accounts payable, shares				37,500
Issuance of common stock in connection with the settlement of notes payable				$ 32		161,968			162,000		162,000
Issuance of common stock in connection with the settlement of notes payable, shares				324,000
Issuance of common stock in connection with the conversion of loans payable				$ 90		318,910			319,000		319,000
Issuance of common stock in connection with the conversion of loans payable, shares				900,793
Issuance of common stock in connection with the conversion of related party notes payable				$ 13		62,487			62,500		62,500
Issuance of common stock in connection with the conversion of related party notes payable, shares				125,000
Issuance of common stock in connection with the conversion of interest payable				$ 5		17,879			17,884		17,884
Issuance of common stock in connection with the conversion of interest payable, shares				50,743
Common stock options issued under employee equity incentive plan						72,587			72,587		72,587
Reclassification of derivative liability to additional paid-in capital						281,315			281,315		281,315
Recognition of beneficial conversion features related to convertible debt instruments
Acquisition of equity interests in subsidiaries
Ending Balance at Dec. 31, 2017	$ 500	$ 50	$ 74	$ 1,390		9,337,431	(8,578,963)		760,482	150,234	910,716
Ending Balance, shares at Dec. 31, 2017	5,000,000	500,000	744,772	13,890,028
Beginning Balance at Sep. 30, 2017	$ 500	$ 50	$ 83	$ 1,073		7,657,982	(7,592,371)		67,317	158,124	225,441
Beginning Balance, shares at Sep. 30, 2017	5,000,000	500,000	832,500	10,732,922
Net income (loss)											(2,679,190)
Change in foreign currency translation
Reclassification of derivative liability to additional paid-in capital											882,454
Ending Balance at Mar. 31, 2018	$ 500	$ 50	$ 55	$ 1,607		12,925,708	(10,258,765)		2,669,155	545,328	3,214,483
Ending Balance, shares at Mar. 31, 2018	5,000,000	500,000	552,500	16,068,505
Beginning Balance at Dec. 31, 2017	$ 500	$ 50	$ 74	$ 1,390		9,337,431	(8,578,963)		760,482	150,234	910,716
Beginning Balance, shares at Dec. 31, 2017	5,000,000	500,000	744,772	13,890,028
Net income (loss)							(1,679,802)		(1,679,802)	(4,906)	(1,684,708)
Change in foreign currency translation
Issuance of common stock in connection with the conversion of Series D preferred stock			$ (19)	$ 48		(29)
Issuance of common stock in connection with the conversion of Series D preferred stock, shares			(192,272)	480,680
Issuance of common stock in connection with sales made under private offerings				$ 2		9,998			10,000		10,000
Issuance of common stock in connection with sales made under private offerings, shares				25,000
Issuance of common stock in connection with the exercise of common stock purchase warrants
Issuance of common stock in connection with the exercise of common stock purchase warrants, shares
Issuance of common stock as compensation to employees, officers and/or directors				$ 5		160,890			160,895		160,895
Issuance of common stock as compensation to employees, officers and/or directors, shares				45,000
Issuance of common stock in exchange for consulting, professional and other services provided				$ 1		38,251			38,252		38,252
Issuance of common stock in exchange for consulting, professional and other services provided, shares				15,000
Issuance of common stock in connection with the settlement of accounts payable
Issuance of common stock in connection with the settlement of accounts payable, shares
Issuance of common stock in connection with the settlement of notes payable
Issuance of common stock in connection with the settlement of notes payable, shares
Issuance of common stock in connection with the conversion of loans payable				$ 97		384,118			384,215		384,215
Issuance of common stock in connection with the conversion of loans payable, shares				968,857
Issuance of common stock in connection with the conversion of related party notes payable
Issuance of common stock in connection with the conversion of related party notes payable, shares
Issuance of common stock in connection with the conversion of interest payable				$ 2		9,384			9,386		9,386
Issuance of common stock in connection with the conversion of interest payable, shares				23,669
Common stock options issued under employee equity incentive plan						995,181			995,181		995,181
Reclassification of derivative liability to additional paid-in capital						601,139			601,139		601,139
Issuance of common stock in satisfaction of debt issuances costs				$ 62		1,389,345			1,389,407		1,389,407
Issuance of common stock in satisfaction of debt issuances costs, shares				620,271
Issuance of common stock in connection with the conversion of debentures
Issuance of common stock in connection with the conversion of debentures, shares
Recognition of beneficial conversion features related to convertible debt instruments
Acquisition of equity interests in subsidiaries										400,000	400,000
Ending Balance at Mar. 31, 2018	$ 500	$ 50	$ 55	$ 1,607		12,925,708	(10,258,765)		2,669,155	545,328	3,214,483
Ending Balance, shares at Mar. 31, 2018	5,000,000	500,000	552,500	16,068,505
Beginning Balance at Sep. 30, 2018	$ 500	$ 50	$ 55	$ 2,326		21,495,621	(19,226,462)	(263,985)	2,008,105	1,934,634	3,942,739
Beginning Balance, shares at Sep. 30, 2018	5,000,000	500,000	552,500	23,255,411
Net income (loss)							(2,596,659)		(2,596,659)	(54,738)	(2,651,397)
Change in foreign currency translation								(179,822)	(179,822)		(179,822)
Issuance of common stock in connection with the conversion of Series D preferred stock			$ (4)	$ 10		(6)			(1)		(1)
Issuance of common stock in connection with the conversion of Series D preferred stock, shares			(38,000)	95,000
Issuance of common stock in connection with sales made under private offerings				$ 20		105,980			106,000		106,000
Issuance of common stock in connection with sales made under private offerings, shares				200,000
Issuance of common stock in connection with the exercise of common stock purchase warrants
Issuance of common stock in connection with the exercise of common stock purchase warrants, shares
Issuance of common stock as compensation to employees, officers and/or directors				$ 5		35,870			35,875		35,875
Issuance of common stock as compensation to employees, officers and/or directors, shares				50,000
Issuance of common stock in exchange for consulting, professional and other services provided				$ 25		128,375			128,400		128,400
Issuance of common stock in exchange for consulting, professional and other services provided, shares				250,000
Issuance of common stock in connection with the conversion of loans payable				$ 78		317,022			317,100		317,100
Issuance of common stock in connection with the conversion of loans payable, shares				779,808
Issuance of common stock in connection with the conversion of interest payable				$ 1		2,987			2,988		2,988
Issuance of common stock in connection with the conversion of interest payable, shares				10,163
Issuance of common stock in connection with the conversion of debentures				$ 67		387,933			388,000		388,000
Issuance of common stock in connection with the conversion of debentures, shares				669,362
Issuance of common stock and common stock purchase warrants in satisfaction of debt issuances costs						12,423			12,423		12,423
Recognition of beneficial conversion features related to convertible debt instruments						280,144			280,144		280,144
Stock based compensation related to employee stock options						169,922			169,922		169,922
Ending Balance at Dec. 31, 2018	$ 500	$ 50	$ 51	$ 2,531		22,936,272	(21,823,121)	(443,807)	672,476	1,879,896	2,552,372
Ending Balance, shares at Dec. 31, 2018	5,000,000	500,000	514,500	25,309,744
Beginning Balance at Sep. 30, 2018	$ 500	$ 50	$ 55	$ 2,326		21,495,621	(19,226,462)	(263,985)	2,008,105	1,934,634	3,942,739
Beginning Balance, shares at Sep. 30, 2018	5,000,000	500,000	552,500	23,255,411
Net income (loss)											(6,489,767)
Change in foreign currency translation											(115,561)
Reclassification of derivative liability to additional paid-in capital
Ending Balance at Mar. 31, 2019	$ 500	$ 50	$ 35	$ 2,709	(406,000)	24,278,682	(25,554,846)	(379,546)	(2,058,416)	1,773,251	(285,165)
Ending Balance, shares at Mar. 31, 2019	5,000,000	500,000	349,500	27,094,744
Beginning Balance at Dec. 31, 2018	$ 500	$ 50	$ 51	$ 2,531		22,936,272	(21,823,121)	(443,807)	672,476	1,879,896	2,552,372
Beginning Balance, shares at Dec. 31, 2018	5,000,000	500,000	514,500	25,309,744
Net income (loss)							(3,731,725)		(3,731,725)	(106,645)	(3,838,400)
Change in foreign currency translation								64,261	64,261		(115,561)
Issuance of common stock in connection with the conversion of Series D preferred stock			$ (16)	$ 41		(24)			1		1
Issuance of common stock in connection with the conversion of Series D preferred stock, shares			(165,000)	412,500
Issuance of common stock in connection with sales made under private offerings				$ 20		79,980			80,000		80,000
Issuance of common stock in connection with sales made under private offerings, shares				200,000
Issuance of common stock in connection with the exercise of common stock purchase warrants
Issuance of common stock in connection with the exercise of common stock purchase warrants, shares
Issuance of common stock as compensation to employees, officers and/or directors				$ 4		19,496			19,500		19,500
Issuance of common stock as compensation to employees, officers and/or directors, shares				37,500
Issuance of common stock in exchange for consulting, professional and other services provided				$ 10		52,990			53,000		53,000
Issuance of common stock in exchange for consulting, professional and other services provided, shares				100,000
Issuance of common stock and common stock purchase warrants in satisfaction of debt issuances costs				$ 2		46,675			46,677		46,677
Issuance of common stock and common stock purchase warrants in satisfaction of debt issuances costs, shares				20,000
Issuance of common stock in connection with stock subscriptions received under private offerings				$ 101	(406,000)	405,899
Issuance of common stock in connection with stock subscriptions received under private offerings, shares				1,015,000
Recognition of beneficial conversion features related to convertible debt instruments						566,841			566,841		566,841
Stock based compensation related to employee stock options						170,553			170,553		170,553
Ending Balance at Mar. 31, 2019	$ 500	$ 50	$ 35	$ 2,709	$ (406,000)	$ 24,278,682	$ (25,554,846)	$ (379,546)	$ (2,058,416)	$ 1,773,251	$ (285,165)
Ending Balance, shares at Mar. 31, 2019	5,000,000	500,000	349,500	27,094,744

Organization, Basis of Presenta

Organization, Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Organization, Basis of Presentation and Significant Accounting Policies	NOTE 1 – ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES EVIO, Inc., a Colorado corporation and its subsidiaries (“the Company”, “EVIO”, “EVIO Labs”, “we”, “us”, or “our”) provide analytical testing and advisory services to the developing legalized cannabis and hemp industries. The Company operates both corporate owned and licensed laboratories through-out North America. Our laboratories provide testing for both cannabis and hemp products at all our labs. Oregon: The Company operates two OLCC licensed and ORELAP accredited laboratories in Oregon. EVIO Labs Portland, located in Tigard, OR, is 100% owned by EVIO. EVIO Labs Medford, located in Central Point, OR is 80% owned by EVIO. California: The Company operates one BCC licensed and ISO 17025 accredited laboratory in Berkeley serving both the cannabis and hemp markets in the state and the hemp market nationwide. EVIO owns 90% of this company. Massachusetts: The Company is completing the relocation and re-accreditation of our laboratory in the state. Florida: The Company licenses its brand to Kaycha Holdings, which operates two ISO 17025 accredited laboratories in the state. Colorado: The Company licenses its brand to Kaycha Holdings, which operates one ISO 17025 accredited laboratory in the state. Canada: The Company operates one Health Canada licensed, GMP certified laboratory, in Edmonton, Alberta. EVIO owns 50% of this company. Basis of Presentation The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited consolidated financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: ● Step 1: Identify the contract with the customer ● Step 2: Identify the performance obligations in the contract ● Step 3: Determine the transaction price ● Step 4: Allocate the transaction price to the performance obligations in the contract ● Step 5: Recognize revenue when the company satisfies a performance obligation The Company generates revenue from consulting services, licensing agreements and testing of cannabis and hemp products for medicinal and adult-use consumption. The Company accounts for a contract after it has been approved by all parties to the arrangement, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company evaluates the services promised in each contract at inception to determine whether the contract should be accounted for as having one or more performance obligations. The Company’s services included in its contracts are distinct from one another. The Company determines the transaction price for each contract based on the consideration it expects to receive for the distinct services being provided under the contract. The Company recognizes revenue as performance obligations are satisfied and the customer obtains control of the services provided. In determining when performance obligations are satisfied, the Company considers factors such as contract terms, payment terms and whether there is an alternative future use of the service. The Company recognizes revenue from testing services upon delivery of its testing results to the client. Customer orders for testing services are generally completed within two weeks of receiving the order. Consulting engagements may vary in length and scope, but will generally include the review and/or preparation of regulatory filings, business plans and financial models, operating plans, and technology support to customers within the same industry. Revenue from consulting services is recognized upon completion of deliverables as outlined in the consulting agreement. The Company recognizes revenue from right of use license agreements upon transfer of control of the functional intellectual property. In certain licensing agreements, the Company may receive royalty revenues based upon performance metrics which are recognized as earned over time. Foreign Currency Translation The functional currency of the Company’s subsidiary in Canada is the Canadian Dollar. The subsidiary’s assets and liabilities have been translated to U.S. Dollars using the exchange rates in effect at the balance sheet dates. Statements of operations amounts have been translated using the average exchange rate for each period. Resulting gains or losses from translating foreign currency financial statements are recorded as other comprehensive income (loss). Fair Value of Financial Instruments The Company has adopted the guidance under ASC Topic 820 for financial instruments measured on a fair value on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Net Income (Loss) Per Share Basic loss per share is computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period. There were 24,753,819 and 11,713,103 potentially dilutive common shares outstanding as of March 31, 2019 and 2018, respectively. Because of the net losses incurred during the six months ended March 31, 2019 and 2018, the impacts of dilutive instruments would have been anti-dilutive for the period presented and have been excluded from the diluted loss per share calculations. Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In January 2017, the FASB issued ASU 2017-04, “ Intangibles—Goodwill and Other (Topic 350), Simplifying the Test for Goodwill Impairment”. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption

Going Concern

Going Concern	6 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going concern The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has negative working capital, recurring losses, and does not have an established source of revenues sufficient to cover its operating costs. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraph and eventually attain profitable operations. The accompanying financial statements do not include any adjustments that may be necessary if the Company is unable to continue as a going concern. In the coming year, the Company’s foreseeable cash requirements will relate to continual development of the operations of its business, maintaining its good standing and making the requisite filings with the Securities and Exchange Commission, and the payment of expenses associated with operations and business developments. The Company may experience a cash shortfall and be required to raise additional capital. Historically, it has mostly relied upon convertible debentures, convertible promissory notes, internally generated funds such as shareholder loans and advances to finance its operations and growth. Management may raise additional capital by retaining net earnings or through future public or private offerings of the Company’s stock or through loans from private investors, although there can be no assurance that it will be able to obtain such financing. The Company’s failure to do so could have a material and adverse effect upon it and its shareholders.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Mar. 31, 2019
Investments, All Other Investments [Abstract]
Fair Value of Financial Instruments	Note 3 – FAIR VALUE OF FINANCIAL INSTRUMENTS ASC Topic 820 establishes a fair value hierarchy, giving the highest priority to quoted prices in active markets and the lowest priority to unobservable data and requires disclosures for assets and liabilities measured at fair value based on their level in the hierarchy. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: ● Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. ● Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. ● Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally cash, accounts payable, and accrued liabilities. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of the Company’s debt approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to the Company. The Company analyzes all financial instruments with features of both liabilities and equity under ASC 480, “Distinguishing Liabilities from Equity” and ASC 815, “Derivatives and Hedging”. Derivative liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded in results of operations as adjustments to fair value of derivatives. The effects of interactions between embedded derivatives are calculated and accounted for in arriving at the overall fair value of the financial instruments. In addition, the fair value of freestanding derivative instruments such as warrant and option derivatives are valued using the Black-Scholes simulation model. The Company’s derivative liabilities were adjusted to fair market value at the end of each reporting period, using Level 3 inputs. The following table sets forth by level with the fair value hierarchy the Company’s financial assets and liabilities measured at fair value on Level 1 Level 2 Level 3 Total Liabilities Derivative financial instruments $ - $ - $ 2,102,387 $ 2,102,387 The following table sets forth by level with the fair value hierarchy the Company’s financial assets and liabilities measured at fair value on September 31, 2018: Level 1 Level 2 Level 3 Total Liabilities Derivative financial instruments $ - $ - $ 1,181,278 $ 1,181,278

Leases

Leases	6 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	Note 4 –leases The Company determines if an arrangement is a lease at inception and has lease agreements for warehouses, office facilities, and equipment. These commitments have remaining non-cancelable lease terms, with lease expirations which range from 2020 to 2024. As a result of the adoption of ASC 842, certain real estate and equipment operating leases have been recorded on the balance sheet with a lease liability and right-of-use asset (“ROU”). Application of this standard resulted in the recognition of ROU assets of $2,667,715, net of accumulated amortization, and a corresponding lease liability of $2,828,361 at the October 1, 2018, date of adoption. Accounting for finance leases is substantially unchanged. Operating leases are included in operating lease ROU assets, operating lease obligations, current, and operating lease obligations, long term on the condensed consolidated balance sheets. Finance leases are included in property and equipment, finance lease obligations, short term, and finance lease obligations, long term, on the condensed consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Amortization of lease assets is included in general and administrative expenses. The future minimum lease payments of lease liabilities as of March 31, 2019, are as follows: Year ended March 31, Operating Leases Financing Leases 2019 662,673 $ 404.795 2020 784,958 354,898 2021 525,852 340,025 2022 489,392 181,372 2023 323,356 204,812 Thereafter 27,911 4,977 Total lease payments 2,814,142 1,490,879 Less: Payments Made (225,192 ) (196,035 ) Total Lease Liabilities $ 2,478,950 $ 1,294,845

Intangible Assets

Intangible Assets	6 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 5 – INTANGIBLE ASSETS The Company’s intangible assets consist of customer lists, testing licenses, favorable leases and websites. The components of intangible assets as of March 31, 2019 and September 30, 2018 consist of: March 31, 2019 September 30, 2018 Customer list $ 849,458 $ 865,672 License 503,000 503,000 Favorable lease 3,100 3,100 Domains & Websites 49,448 49,690 Non-compete agreements 181,538 184,563 Assembled Workforce 50,750 50,750 Intellectual Property 332,868 342,610 Total 1,970,162 1,999,385 Accumulated amortization (506,945 ) (318,815 ) Net value $ 1,463,217 $ 1,680,570 The Company estimates amortization to be recorded on existing intangible assets through the year ended September 30, 2030 to be: Amortization 2019 $ 193,959 2020 346,656 2021 307,469 2022 238,289 2023 197,765 2024 124,847 2025 44,097 2026 2,317 2027 2,317 2028 2,317 2029 2,317 2030 868 Total $ 1,463,217

Concentration of Credit Risk

Concentration of Credit Risk	6 Months Ended
	Mar. 31, 2019
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	Note 6 – Concentration of Credit Risk Instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits, notes receivable and accounts receivable. As of March 31, 2019, the Company did not hold cash at any financial institution in excess of the amount insured by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000. As of both March 31, 2019 and September 30, 2018, the Company had a note receivable totaling $1,300,000 due from a single entity. Customer Concentrations During the six months ended March 31, 2019, there was no customers that represented over 10% of the Company’s revenues. During the six months ended March 31, 2018, no customer represented over 10% of the Company’s revenues. As of March 31, 2019, there was one customer who represented 32% of accounts receivable. As of May 31, 2018, there were no customers who represented more than 10% of accounts receivable. As of March 31, 2019, the Company had total accounts receivable net of allowances of $122,783. Three clients comprised a total of 36% of this balance as follows: Balance Percent of Total Customer 1 $ 180,000 32 % Customer 2 29,063 5 % Customer 3 22,740 4 % All others 325,034 58 % Total 556,837 100 % Allowance for doubtful accounts (434,054 ) Net accounts receivable $ 122,783 As of September 30, 2018, the Company had total accounts receivable, net of allowances, of $234,178. Three separate clients comprised a total of 36% of this balance as follows: Balance Percent of Total Customer 1 $ 180,000 27 % Customer 2 34,268 5 % Customer 3 27,317 4 % All others 427,680 64 % Total 669,265 100 % Allowance for doubtful accounts (417,610 ) Net accounts receivable $ 251,655

Property and Equipment

Property and Equipment	6 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment Property and equipment are carried at cost. Expenditures for maintenance and repairs are expensed in the period incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. Depreciation is computed for financial statement purposes on a straight-line basis over estimated useful lives of the related assets and the modified accelerated cost recovery system for federal income tax purposes. The estimated useful lives of depreciable assets are: Estimated Useful Lives Building 39 years Laboratory and Computer Equipment 5 years Furniture and Fixtures 7 years Software 3 years Domains 15 years The Company’s property and equipment consisted of the following as of March 31, 2019 and September 30, 2018: March 31, 2019 September 30, 2018 Assets Not-In-Service $ - $ 455,540 Capital Assets 1,287,091 535,095 Land 212,550 212,550 Buildings & Real Estate 941,857 937,450 Furniture and Equipment 187,602 189,459 Laboratory Equipment 2,651,312 2,468,141 Software 73,908 63,913 Leasehold Improvements 582,695 303,331 Vehicles 83,915 83,915 Total 6,020,931 5,249,394 Accumulated depreciation (1,127,091 ) (644,291 ) Net value $ 4,893,839 $ 4,605,103 During the six months ended March 31, 2019, the Company capitalized a total of $738,141 of equipment and depreciation expense of $230,454.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 – Related Party Transactions During the six months ended March 31, 2019, the Company received loans from its Chief Operating Officer totaling $15,000 and made repayments totaling $1,040 leaving a balance due as of March 31, 2019 of $13,960. The advances are non-interest bearing and due on demand. There was $13,960 and $0 due as of March 31, 2019 and September 30, 2018 and is included in the accompanying consolidated balance sheets as a current portion of notes payable to related parties. During the six months ended March 31, 2019 the Company made payments to Sara Lausmann, associated with the asset purchase of Oregon Analytical Services, LLC, totaling $9,000. There was $571,299 and $580,299 of principal due as of March 31, 2019 and September 30, 2018, respectively. The note carries interest at a rate of 5% per annum and had accrued interest totaling $93,653 and $79,295 due as of March 31, 2019 and September 30, 2018, respectively. During the six months ended March 31, 2019, the Company made $12,000 in payments to Anthony Smith, our Chief Science Officer, associated with the purchase of 80% of Smith Scientific Industries. There was $224,000 and $236,000 of principal due as of March 31, 2019 and September 30, 2018, respectively. The note carries interest at a rate of 5% per annum and had accrued interest totaling $36,696 and $30,960 due as of March 31, 2019 and September 30, 2018, respectively. During the six months ended March 31, 2019, the Company made repayments to Henry Grimmett, prior Company Director (retired April 2018), on an outstanding loan from member assumed by the Company, totaling a note payable of Greenhaus Analytical Services, LLC, totaling $3,858.85. There was $113,554 and $117,412 of principal due as of March 31, 2019 and September 30, 2018, respectively. The note bears interest at 0% per annum and requires repayments of $25,000 quarterly. During the six months ended March 31, 2019, the Company made no payments to Henry Grimmett, prior Company Director (retired April 2018), associated with the acquisition of Greenhaus Analytical Services, LLC. The Company entered into a $340,000 note payable as part of its acquisition of Greenhaus Analytical Services, LLC. The note carries interest at a rate of 6% per annum and matures on October 16, 2020. There was $340,000 of principal as of March 31, 2019 and September 30, 2018. Unamortized debt discount of $39,302 and $51,971 as of March 31, 2019 and September 30, 2018, respectively and $50,078 and $39,905 of accrued interest due as of March 31, 2019 and September 30, 2018, respectively. During the six months ended March 31, 2019, the Company received $119,937 from a related party associate with Keystone Labs and made repayment of $25,886, leaving balances due of $249,546 and $153,177 as of March 31, 2019 and September 30, 2018, respectively. Amounts have been adjusted for USD. The advances are non-interest bearing and due on demand and is included in the accompanying consolidated balance sheets as a current portion of notes payable to related parties.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Stockholders' Equity	Note 9 – STOCKHOLDERS’ EQUITY Series A Convertible Preferred Stock The Company has 0 shares of Series A Convertible Stock issued and outstanding as of March 31, 2019 and 2018. Series B Convertible Preferred Stock The Company designated 5,000,000 shares of Series B Convertible Preferred Stock (“Series B Preferred Stock”) with a par value of $0.0001 per share. The Company has 5,000,000 shares of Series B Convertible Stock issued and outstanding as of March 31, 2019 and 2018. These shares converted to common stock at a rate of 1 common share per each shares of Series B Convertible Preferred Stock. Series C Convertible Preferred Stock The Company designated 500,000 shares of Series C Convertible Preferred Stock (“Series C Preferred Stock”) with a par value of $0.0001 per share. There were 500,000 shares of Series C Convertible Stock issued and outstanding as of March 31, 2019 and 2018. These shares converted to common stock at a rate of 5 common shares per each shares of Series C Convertible Preferred Stock. Series D Convertible Preferred Stock The Company designated 1,000,000 shares of Series D Convertible Preferred Stock (“Series D Preferred Stock”) with a par value of $0.0001 per share. These shares converted to common stock at a rate of 2.5 common shares per each shares of Series D Convertible Preferred Stock. During the six months ended March 31, 2019, the Company received conversion notices from Series D Preferred Stockholders resulting in a total of 507,500 shares of common stock being issued for the conversion of 203,000 shares of Series D Preferred Stock. During the six months ended March 31, 2018, the Company received conversion notices from Series D Preferred Stockholders resulting in a total of 700,000 shares of common stock being issued for the conversion of 280,000 shares of Series D Preferred Stock. There were 349,500 and 552,500 shares of Series D Convertible Stock issued and outstanding as March 31, 2019 and March 31, 2018, respectively. Common Stock During the six months ended March 31, 2019, the Company issued 350,000 common shares valued at $181,400 for services; 400,000 common shares for cash proceeds of $186,000; 1,015,000 common shares for stock subscription of $406,000, 87,500 common shares valued at $55,375 under its employee equity incentive plan; 779,808 common shares for the conversion of $317,100 of outstanding principal on convertible notes payable; 669,362 common shares for the conversion of $388,000 of convertible debentures; 10,163 common shares for conversion of interest payable of $2,988; 507,500 common shares for the conversion of Preferred Series D stock, and 20,000 common shares valued at $11,760 for debt issue costs. All conversions of outstanding principal and accrued interest on convertible notes payable were done so at contractual terms. During the six months ended March 31, 2018, the Company issued 207,750 common shares valued at $254,720 for services; 700,000 common shares for the conversion of 280,000 shares of Series D Preferred Stock; 1,270,000 common shares for cash proceeds of $508,000; 57,000 common shares valued at $75,755 under its employee equity incentive plan under which a total expense of $166,647 was recorded; 37,500 common shares for the settlement of $15,000 of accounts payable; 1,869,650 common shares for the conversion of $703,215 of outstanding principal on convertible notes payable; 74,412 for the conversion of $27,270 of convertible accrued interest; 324,000 common shares for the settlement of non-convertible debt and interest totaling $122,157; 125,000 common shares for the settlement of non-convertible related party debt totaling $50,000 and 670,271 common shares valued at $1,414,907 for debt issue costs from a capital raise. All conversions of outstanding principal and accrued interest on convertible notes payable were done so at contractual terms There were 27,094,744 and 16,068,505 shares of common stock issued and outstanding at March 31, 2019 and March 31, 2018, respectively.

Loans Payable

Loans Payable	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Loans Payable	Note 10 – LOANS PAYABLE The Company had the following loans payable outstanding as of March 31, 2019 and September 30, 2018: March 31, 2019 September 30, 2018 On March 16, 2017, the Company executed notes payable for the purchase of three vehicles. The notes carry interest at 6.637% annually and mature on March 31, 2023. 53,476 60,477 On September 6, 2017, the Company entered into a note payable totaling $1,000,000 for the purchase of an outstanding note receivable. The note carries interest at 8% annually and is due on July 6, 2018. - 500,000 On June 28, 2018, the Company executed a note payable for $650,000 for the purchase of the building at 14775 SW 74 th 634,617 646,231 On July 5, 2018, the Company executed a note payable for $750,000 for the asset purchase of MRX Labs. The note carries interest at 8% annually and is due on January 5, 2019. 750,000 750,000 1,438,093 1,956,708 Less: unamortized original issue discounts - (119,000 ) Total loans payable 1,438,093 1,837,708 Less: current portion of loans payable 786,729 643,627 Long-term portion of loans payable $ 651,364 $ 1,193,781 As of March 31, 2019 and September 30, 2018, the Company accrued interest of $45,834 and $47,767 respectively

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 11 – Convertible NOTES PAYABLE The Company has entered into convertible notes payable that convert to common stock of the Company at variable conversion prices. As further discussed in Note 13 – Derivative Liability The following table summarizes all convertible notes outstanding as of March 31, 2019: Holder Issue Date Due Date Principal Unamortized Debt Discount Carrying Value Accrued Interest Noteholder 2 7/2/18 10/1/18 220,000 - 220,000 13,116 Noteholder 3 7/2/18 10/1/18 220,000 - 220,000 13,116 Noteholder 4 8/1/18 1/1/19 330,000 - 330,000 17,504 Noteholder 5 8/29/18 2/28/19 222,222 - 222,222 6,514 Noteholder 6 9/6/18 9/6/19 125,000 (37,887 ) 87,113 7,055 Noteholder 3 9/13/18 3/11/19 435,000 - 435,000 - Noteholder 7 9/17/18 9/17/19 62,500 (26,327 ) 36,173 3,339 Noteholder 4 10/2/18 1/1/19 220,000 - 220,000 8,679 Noteholder 8 11/15/18 11/15/19 222,600 (139,659 ) 82,941 6,635 Noteholder 9 12/27/18 12/27/19 105,000 (78,248 ) 26,753 2,140 Noteholder 9 12/27/18 12/27/19 131,250 (111,832 ) 19,418 2,186 Noteholder 8 11/15/18 11/15/19 265,000 (224,168 ) 40,832 3,195 Noteholder 9 131,250 (113,990 ) 17,260 1,553 Noteholder 11 580,537 (59,930 ) 520,607 8,112 Noteholder 10 4/24/18 4/24/19 500,000 - 500,000 - $ 3,770,359 $ (792,040 ) $ 2,978,319 $ 93,144 The following table summarizes all convertible notes outstanding as of September 30, 2018: Holder Issue Date Due Date Principal Unamortized Debt Discount Carrying Value Accrued Interest Noteholder 2 7/2/18 10/1/18 220,000 (220 ) 219,780 4,340 Noteholder 3 7/2/18 10/1/18 220,000 (220 ) 219,780 4,340 Noteholder 4 8/1/18 10/1/18 330,000 (492 ) 329,508 - Noteholder 1 8/14/18 8/14/19 167,100 (13,591 ) 153,509 2,839 Noteholder 5 8/29/18 2/28/19 222,222 (78,670 ) 143,552 - Noteholder 6 9/6/18 9/6/19 125,000 (89,921 ) 35,079 - Noteholder 3 9/13/18 3/11/19 585,000 (513,062 ) 71,938 - Noteholder 7 9/17/18 9/17/19 62,500 (57,381 ) 5,119 - Noteholder 10 4/24/18 4/24/19 500,000 0 500,000 - $ 2,431,822 $ (753,557 ) $ 1,678,265 $ 11,519 Noteholder 1 On August 14, 2017, the Company sold and issued a Convertible Promissory Note to an unrelated party, for the principal amount of $275,600 of which $15,600 was an original issue discount and $10,000 was paid directly to third parties resulting in cash proceeds to the Company of $250,000 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 8%, is due on August 14, 2018. The Note is convertible into the Company’s common stock commencing 180 days from the date of issuance at a conversion price equal to 75% of the lowest trade price of the Company’s common stock for the fifteen prior trading days including the date of conversion. During the year ended September 30, 2018, the holder elected to convert $167,100 of principal due in exchange for 479,848 shares of common stock and the holder elected to convert $2,988 of interest due in exchange for 10,163 shares of common stock. There was $0 and $167,100 of principal and $0 and $2,839 of accrued interest due at March 31, 2019 and September 30, 2018, respectively. Noteholder 2 On July 2, 2018, the Company sold and issued a Convertible Promissory to an unrelated party for the principal amount of $220,000 of which $20,000 was an original issue discount and $17,000 was paid directly to third parties resulting in cash proceeds to the Company of $183,000 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 8%, is due on October 1, 2018. The principal amount of the note and any accrued interest thereon are convertible at the option of the holder into common shares of the Company at any time at a conversion price of $0.60 per share. There was $220,000 and $220,000 of principal and $13,116 and $4,340 of accrued interest due March 31, 2019 and September 30, 2018, respectively. Noteholder 3 On July 2, 2018, the Company sold and issued a Convertible Promissory to an unrelated party for the principal amount of $220,000 of which $20,000 was an original issue discount resulting in cash proceeds to the Company of $200,000 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 8%, is due on October 1, 2018. The principal amount of the note and any accrued interest thereon are convertible at the option of the holder into common shares of the Company at any time at a conversion price of $0.60 per share. There was $220,000 and $220,000 of principal and $13,116 and $4,340 of accrued interest due March 31, 2019 and September 30, 2018, respectively. On September 17, 2018, the Company entered into an exchange agreement with an unrelated party for the principal amount $585,000, of which the loan payable to Palliatech, Dated August 1, 2017, outstanding and principal of $549,652 would be assumed by the new note holder, with difference of $35,348 to be treated as an original issue discount. The new convertible note payable carries an interest rate of 0% per annum is convertible into common stock of the Company at the option of the noteholder immediately at 80% of the lowest volume weighted average price of the Company’s common stock in the preceding 20 trading days. There was $435,000 of principal and $0 accrued interest due on both March 31, 2019 and September 30, 2018. Noteholder 4 On August 1, 2018, the Company sold and issued a Convertible Promissory to an unrelated party for the principal amount of $330,000 of which $30,000 was an original issue discount resulting in cash proceeds to the Company of $300,000 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 8%, was due on October 1, 2018. The principal amount of the note and any accrued interest thereon are convertible at the option of the holder into common shares of the Company at any time at a conversion price of $0.60 per share. There was $330,000 and $330,000 of principal and $17,504 and $10,994 of accrued interest due at March 31, 2019 and September 30, 2018, respectively. On October 2, 2018, the Company sold and issued a Convertible Promissory to an unrelated party for the principal amount of $220,000 of which $20,000 was an original issue discount resulting in cash proceeds to the Company of $200,000 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 8%, is due on January 1, 2019. The principal amount of the note and any accrued interest thereon are convertible at the option of the holder into common shares of the Company at any time at a conversion price of $0.60 per share. There was $220,000 of principal and $8,679 of accrued interest due at March 31, 2019. Noteholder 5 On August 29, 2018, the Company sold and issued a Convertible Promissory to an unrelated party for the principal amount of $222,222 of which $22,222 was an original issue discount and $5,500 was paid directly to third parties resulting in cash proceeds to the Company of $194,500 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 5%, is due on February 28, 2019. The principal amount of the note and any accrued interest thereon are convertible at the option of the holder into common shares of the Company at any time at a conversion price of $0.70 per share. There was $222,222 and $222,222 of principal and $3,775 and $0 of accrued interest due at March 31, 2019 and September 30, 2018, respectively. The holder has issued a notice of default on this promissory note. Noteholder 6 On September 6, 2018, the Company sold and issued a Convertible Promissory to an unrelated party for the principal amount of $125,000 of which $15,000 was an original issue discount parties resulting in cash proceeds to the Company of $110,000 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 10%, is due on September 6, 2019. The principal amount of the note and any accrued interest thereon are convertible at the option of the holder into common shares of the Company at any time at a conversion price of $0.50 per share. There was $125,000 and $125,000 of principal and $7,055 and $0 of accrued interest due at March 31, 2019 and September 30, 2018, respectively. Noteholder 7 On September 6, 2018, the Company sold and issued a Convertible Promissory to an unrelated party for the principal amount of $62,500 of which $6,250 was an original issue discount resulting in cash proceeds to the Company of $56,250 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 10%, is due on September 6, 2019. The principal amount of the note and any accrued interest thereon are convertible at the option of the holder into common shares of the Company at any time at a conversion price of $0.50 per share. There was $62,500 and $62,500 of principal and $3,339 and $0 of accrued interest due at March 31, 2019 and September 30, 2018, respectively. Noteholder 8 On November 15, 2018, the Company sold and issued a Convertible Promissory to an unrelated party for the principal amount of $222,600 of which $12,600 was an original issue discount resulting in cash proceeds to the Company of $210,000 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 8%, is due on November 15, 2019. The principal amount of the note and any accrued interest thereon are convertible at the option of the holder into common shares of the Company at any time at a conversion price of $0.55 per share. There was $222,600 of principal and $6,635 of accrued interest due at March 31, 2019. On February 4, 2019, the Company entered into a convertible note payable with an unrelated party for $265,000 of which $15,000 was an original issue discount and $10,000 in third party fees resulting in net cash proceeds to the Company of $240,000. The convertible note payable carries interest at a rate of 8% per annum, is due on February 4, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company’s common stock in the preceding 15 trading days. There was $265,000 of principal and $3,195 of accrued interest due at March 31, 2019. Noteholder 9 On December 27, 2018, the Company sold and issued a Convertible Promissory to an unrelated party for the principal amount of $105,000 pursuant to the terms of a Securities Purchase Agreement of even date therewith. The Note, together with accrued interest at the annual rate of 8%, is due on December 27, 2019. The Note is convertible into the Company’s common stock commencing 180 days from the date of issuance at a conversion price equal to 65% of the lowest trade price of the Company’s common stock for the fifteen prior trading days including the date of conversion. There was $105,000 of principal and $2,140 of accrued interest due at March 31, 2019. On January 14, 2019, the Company entered into a convertible note payable with an unrelated party for $131,250 of which included $6,250 in third party fees resulting in net cash proceeds to the Company of $125,000. The convertible note payable carries interest at a rate of 8% per annum, is due on January 14, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company’s common stock in the preceding 15 trading days. There was $131,250 of principal and $2,186 of accrued interest due at March 31, 2019. On February 4, 2019, the Company entered into a convertible note payable with an unrelated party for $131,250 of which included $6,250 in third party fees resulting in net cash proceeds to the Company of $125,000. The convertible note payable carries interest at a rate of 8% per annum, is due on February 4, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company’s common stock in the preceding 15 trading days. There was $131,250 of principal and $1,553 of accrued interest due at March 31, 2019. Noteholder 10 On April 24, 2018, the Company entered into a convertible note payable totaling $500,000 in exchange for 100% of the assets of Leaf Detective LLC. The note bears no interest, matures on April 24, 2019 and automatically converted to common stock at $1.25 per share on the maturity date. In the event the average lowest trading price of the Company’s common stock during the five days prior to maturity is less than $1.25 per share, the Company will pay the noteholder the difference between $1.25 and the average lowest trading price during the preceding five days per share converted in cash. There was $500,000 principal and $0 interest due on both March 31, 2019 and September 30, 2018. Noteholder 11 On February 8, 2019, the Company entered into an exchange agreement with an unrelated party for $580,537, of which the loan payable to Palliatech, dated September 1, 2017, outstanding and principal would be assumed by the new note holder. The new convertible note payable carries an interest rate of 10% per annum, with one year interest guaranteed, is due on February 8, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 30% discount from the lowest trading price of the Company’s common stock in the preceding 15 trading days. There was $580,537 of principal and $8,112 of accrued interest due at March 31, 2019.

Convertible Debentures

Convertible Debentures	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Convertible Debentures	NOTE 12 – CONVERTIBLE DEBENTURES On January 29, 2018, the Company issued a total of 5,973 units of 8% unsecured convertible debentures. Each unit consists of one convertible debenture with a principal face value of $1,000 and 250 warrants. The gross proceeds were $5,973,000. Each warrant entitles the holder thereof to purchase one additional common share of the Company at an exercise price of $0.80 per warrant for a period of 24 months. The convertible debentures have a maturity date of 36 months from issuance. Simple interest will be paid at a rate of 8% per annum in arrears until maturity or until conversion. The principal amount of the debentures and any accrued interest thereon are convertible at the option of the holder into common shares of the Company at any time at a conversion price of $0.60 per share. In addition to the warrants associated with the convertible debentures, the Company issued an additional 597,300 warrants to purchase common stock of the Company as offering costs representing an equivalent of 6% of the fully converted debentures. The warrants are exercisable at $0.60 per share for a period of two years. During the fiscal year ended September 30, 2018, the Company issued three separate debentures under the same terms for additional cash proceeds of $610,000. The additional debentures carry an additional 152,500 warrants to purchase additional common shares of the Company at $0.80 per share. Additionally, the outstanding principal and interest may be converted to common stock of the Company at $0.60 per share. During the six month quarter ended March 31, 2019, the Company also issued nineteen additional debentures under the same terms for additional cash proceeds of $374,000. The additional debentures carry an additional 187,000 warrants to purchase additional common shares of the Company at $0.80 per share. Additionally, the outstanding principal and interest may be converted to common stock of the Company at $0.60 per share. Associated with the issuance of the convertible debentures, the Company incurred cash-based issuance costs of $702,963, issued common shares valued at $1,414,907 and warrants to purchase additional shares of common stock valued at $1,265,385 for total debt issuance costs of $3,383,255. The debt issuance costs were recorded as a discount to the carrying value of the convertible debentures. The warrants associated with the debt issue costs were valued using a Black-Scholes model with the following assumptions: Expected term of options granted 2 years Expected volatility 223 % Risk-free interest rate 2.49 % Expected dividend yield 0 % The Company separately assessed the value of the detachable warrants and conversion features of the convertible debentures. The Company separately initially valued the detachable warrants issued with the convertible debentures at $3,351,160 using a Black-Scholes model with the following assumptions: Expected term of options granted 2 years Expected volatility 211 - 223 % Risk-free interest rate 2.09 - 2.25 % Expected dividend yield 0 % Additionally, the outstanding principal on convertible debentures totaling $6,957,000 may be converted into common stock of the Company at $0.60 per share for a total of 11,595,000 shares. Due to the variable conversion features of the outstanding convertible notes payable as discussed in Note 7 – Convertible Notes Payable As of March 31, 2019 the Company has amortized $698,521 of the total outstanding debt discount leaving an unamortized debt discount of $3,484,269. The remaining debt discount will be amortized to interest expense over the expected life of the note. There was $5,183,000 of principal and accrued interest totaling $446,427 outstanding as of March 31, 2019.

Derivative Liability

Derivative Liability	6 Months Ended
	Mar. 31, 2019
Derivative Liability [Abstract]
Derivative Liability	Note 13 – Derivative Liability As of March 31, 2019 and September 30, 2018, Company had a derivative liability balance of $2,102,387 and $1,181,278 on the balance sheets and recorded a loss of $556,647 from derivative liability fair value adjustments during the six months ended March 31, 2019. On November 15, 2018, the Company issued a $222,600 convertible promissory note to an unrelated party that matures on November 15, 2019. Refer to Noteholder 8 under “Note 12 – Convertible Debentures” Derivatives and Hedging The embedded derivative for the note is carried on the Company’s balance sheet at fair value. The derivative liability is marked-to-market each measurement period and any unrealized change in fair value is recorded as a component of the income statement and the associated fair value carrying amount on the balance sheet is adjusted by the change. The Company fair values the embedded derivative using the Black-Scholes option pricing model. The aggregate fair value of the derivative at the issuance date of the note was $220,463 which was recorded as a derivative liability on the balance sheet. The Company recorded a debt discount of $184,957 which was up to the face value of the convertible note with the excess fair value at initial measurement of $35,506 being recognized as a loss on derivative fair value measurement. On December 27, 2018, the Company issued a $105,000 convertible promissory note to an unrelated party that matures on December 27, 2019. Refer to Noteholder 9 under “Note 12 – Convertible Debentures” The aggregate fair value of the derivative at the issuance date of the note was $98,091 which was recorded as a derivative liability on the balance sheet. The Company recorded a debt discount of $38,365 which was up to the face value of the convertible note with the excess fair value at initial measurement of $59,725 being recognized as a loss on derivative fair value measurement. On February 4, 2019, the Company issued a $265,000 convertible promissory note to an unrelated party that matures on February 4, 2020. Refer to Noteholder 8 under “Note 12 – Convertible Debentures” The aggregate fair value of the derivative at the issuance date of the note was $322,521 which was recorded as a derivative liability on the balance sheet. The Company recognized a loss of $322,521 on derivative fair value measurement. On February 5, 2019, the Company issued a $131,250 convertible promissory note to an unrelated party that matures on February 5, 2020. Refer to Noteholder 9 under “Note 12 – Convertible Debentures” The aggregate fair value of the derivative at the issuance date of the note was $144,752 which was recorded as a derivative liability on the balance sheet. The Company recorded a debt discount of $14,423 which was up to the face value of the convertible note with the excess fair value at initial measurement of $130,329 being recognized as a loss on derivative fair value measurement. On February 11, 2019, the Company issued a $131,250 convertible promissory note to an unrelated party that matures on February 11, 2020. Refer to Noteholder 9 under “Note 12 – Convertible Debentures” The aggregate fair value of the derivative at the issuance date of the note was $228,916 which was recorded as a derivative liability on the balance sheet. The Company recognized a loss of $228,916 on derivative fair value measurement. At March 31, 2019, the Company marked-to-market the fair value of the derivative liabilities related to conversion features and determined an aggregate fair value of $1,445,738 and recorded a $430,636 loss from change in fair value for the six months ended March 31, 2019. The fair value of the embedded derivatives was determined using a Black-Scholes option pricing model based on the following assumptions: (1) expected volatility of 110%, (2) risk-free interest rate of 2.40%, (3) exercise prices of $0.21 - $0.31, and (4) expected lives of 0.63 – 0.87 years. On October 2, 2018, the Company issued a total of $220,000 convertible debenture to an unrelated party that matures on January 1, 2019. The Company issued a total of 100,000 warrants to purchase additional shares of common stock of the Company in connection with the convertible debenture. The Company analyzed the issued warrants for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the warrants should be classified as a derivative because the Company is unable to ascertain there will be adequate unissued authorized shares of common stock to fulfill its obligations should the warrants be exercised. In accordance with AC 815, the Company has recorded a derivative liability related to the warrants. The derivative for the warrants is carried on the Company’s balance sheet at fair value. The derivative liability is marked-to-market each measurement period and any unrealized change in fair value is recorded as a component of the income statement and the associated fair value carrying amount on the balance sheet is adjusted by the change. The Company fair values the derivative using the Black-Scholes option pricing model. The aggregate fair value of the derivative at the issuance date of the warrants was $57,014 which was recorded as a derivative liability on the balance sheet. The Company recorded a debt discount of $53,333 which was up to the face value of the convertible debentures with the excess fair value at initial measurement of $3,681 being recognized as a loss on derivative fair value measurement. As discussed in “Note 12 – Convertible Debentures” At March 31, 2019, the Company marked-to-market the fair value of the derivative liabilities related to warrants and determined an aggregate fair value of $627,792 and recorded a $651,427 gain from change in fair value for the six months ended March 31, 2019. The fair value of the derivatives was determined using a Black-Scholes option pricing model based on the following assumptions: (1) expected volatility of 110%, (2) risk-free interest rate of 2.40%, (3) exercise prices of $0.60 to $0.80, and (4) expected lives of 0.87 – 0.99 of a year. The following table summarizes the derivative liabilities included in the balance sheet at March 31, 2019: Fair Value of Derivative Liabilities: Balance, September 30, 2018 $ 1,181,278 Initial measurement of derivative liabilities 1,145,140 Change in fair market value (224,021 ) Write off due to conversion - Balance, March 31, 2019 $ 2,102,387 The following table summarizes the gain (loss) on derivative liability included in the income statement for the six months ended March 31, 2019 and 2018, respectively. March 31, 2018 2017 Day one loss due to derivatives on convertible debt $ (780,678 ) $ (352,206 ) Change in fair value of derivatives 224,021 160,928 Total derivative gain (loss) $ (556,647 ) $ (191,278 )

Stock Options and Warrants

Stock Options and Warrants	6 Months Ended
	Mar. 31, 2019
Stock Options And Warrants
Stock Options and Warrants	NOTE 14 – STOCK OPTIONS AND WARRANTS The following table summarizes all stock option and warrant activity for the six months ended March 31, 2019: Shares Weighted-Average Outstanding, September 30, 2018 4,638,050 $ 0.784 Granted 646,920 0.610 Exercised - Forfeited - - Expired - - Outstanding, March 31, 2019 5,284,970 $ 0.764 The following table discloses information regarding outstanding and exercisable options and warrants at March 31, 2019: Outstanding Exercisable Exercise Prices Number of Option Shares Weighted Weighted Average Number of Option Shares Weighted Average Exercise Price $ 0.400 110,000 $ 0.400 2.38 110,000 $ 0.400 $ 0.420 330,000 $ 0.420 4.80 330,000 $ 0.420 $ 0.500 165,000 $ 0.500 2.45 162,500 $ 0.500 $ 0.600 627,220 $ 0.600 0.87 627,220 $ 0.600 $ 0.650 145,000 $ 0.650 3.57 36,250 $ 0.650 $ 0.800 3,482,750 $ 0.800 2.19 3,095,250 $ 0.800 $ 0.850 100,000 $ 0.850 4.05 - $ 0.850 $ 1.050 25,000 $ 1.050 4.55 - $ 1.050 $ 1.260 220,000 $ 1.260 3.25 110,000 $ 1.260 $ 1.300 10,000 $ 1.300 2.56 7,500 $ 1.300 $ 1.386 60,000 $ 1.386 3.25 30,000 $ 1.386 $ 1.666 10,000 $ 1.666 3.34 5,000 1.666 Total 5,284,970 $ 0.783 2.82 4,513,720 $ 0.764 In determining the compensation cost of the stock options granted, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes option pricing model. The assumptions used in these calculations are summarized as follows: March 31, 2019 Expected term of options granted 1.1 to 5.0 years Expected volatility 102.63 to 122.49 % Risk-free interest rate 2.57 to 2.67 % Expected dividend yield 0 % The Company recognized stock option expense of $169,922 and $72,587 during the three months ended March 31, 2019 and 2018, respectively. There was $787,907 of unrecognized stock-based compensation expense as of March 31, 2019.

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 15 – Subsequent Events Common Stock Issuances The Company made the following issuances of common stock subsequent to March 31, 2019: ● 25,000 common shares for the conversion of 10,000 shares of Series D Preferred Stock. ● 58,245 common shares for the settlement of $21,000 of accounts payable. ● 12,500 common shares valued at $6,624 for the vesting of restricted stock grants for officers and directors ● 688,017 common shares for services valued at $192,390 ● 1,201,420 common shares for the conversion of $357,222 of outstanding principal on convertible notes payable. ● 381,351 common shares for the settlement of $165,000 of outstanding interest and penalties on convertible notes payable. Equity Raise with Warrants On April 8, 2019, the Company raised an aggregate amount of $586,000, in accordance with Regulation S under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States or to a U.S. persons (as defined in Regulation S under the U.S. Securities Act) absent registration or an applicable exemption from registration requirements. A portion of the Offering was completed on a best efforts basis through lead agent and bookrunner Dominick Capital Corporation of Toronto, Canada. A total of 1,465,000 Units were sold in this transaction, each Unit consists of one share of EVIO common stock (“Stock”) at a price of $0.40, and a share purchase warrant (each, a “Warrant”) in the amount of one full Warrant per Unit. Each whole Warrant shall entitle the holder thereof to purchase one additional common share of the Offeror (each a “Warrant Share”) at an exercise price of US $0.65 per Warrant Share for a period of 24 months after the closing of the Offering Convertible Notes Payable On August 8, 2019, the Company entered into a convertible note payable with an unrelated party for $33,092 which included $1,575 third party fees resulting in net cash proceeds to the Company of $31,517. The convertible note payable carries interest at a rate of 8% per annum, is due on August 8, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company’s common stock in the preceding 15 trading days. On August 8, 2019, the Company entered into a convertible note payable with an unrelated party for $33,092 which included $1,575 third party fees resulting in net cash proceeds to the Company of $31,517. The convertible note payable carries interest at a rate of 8% per annum, is due on August 8, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company’s common stock in the preceding 15 trading days. On August 30, 2019, the Company entered into a convertible note payable with an unrelated party for $110,000 which included $10,000 original issue discount resulting in net cash proceeds to the Company of $100,000. The convertible note payable carries interest at a rate of 8% per annum, is due on May 30, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company’s common stock in the preceding 15 trading days. Convertible Notes Payable – Exchanged Note On August 29, 2019, the Company entered into an exchange agreement with an unrelated party for $199,203, of which the loan payable to Henry Grimmett, dated October 16, 2016, outstanding and principal would be assumed by the new note holder. The new convertible note payable carries an interest rate of 8% per annum, is due on May 29, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company’s common stock in the preceding 15 trading days. Debenture Holders Offer On June 16, 2019 the Company offered current Debenture Holders a one-time opportunity to lower the Conversion Price of the Debenture to US$0.40 per share (the “Amended Conversion Price”); provided, however, that Investor agrees to defer interest under the Debenture until the Maturity Date identified in the Debenture, and further agrees to have any and all accrued and unpaid interest automatically converted into Common Shares of the Company at the Amended Conversion Price on the Maturity Date The original debenture had a conversion rate of US$0.60 per share. At the time of the offer there were $5,183,000 in outstanding debentures. To date a total of $4,654,000 of have opted for the offer, and $529,000 have yet to accept the offer. The additional shares to be issued related to accepted offers is 3,878,333. Equipment Financing On April 24, 2019 the Company entered into an equipment lease arrangement with Sweet Leaf Capital. The term of the lease is 30 months, commencing June 1, 2019. The capital cost of the equipment financed is $467,837.00. The agreement calls for an initial payment of $67,459, followed by 30 payments in the amount of $18,226.00. The Company will record this as a capital lease obligation in Q3, 2019. Legal Proceedings On May 9, 2019, Stephanie Head, a former part-time lab administrator for EVIO Labs Eugene, LLC, filed a wrongful termination lawsuit with the US District Court - District of Oregon, Eugene Division, Case No. 6:19-CV-00681, against EVIO Labs Eugene, LLC, EVIO, Inc. and Lori Glauser. This case is still in process. Complaint - Breach of Promissory Note th

Organization, Basis of Presen_2

Organization, Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited consolidated financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: ● Step 1: Identify the contract with the customer ● Step 2: Identify the performance obligations in the contract ● Step 3: Determine the transaction price ● Step 4: Allocate the transaction price to the performance obligations in the contract ● Step 5: Recognize revenue when the company satisfies a performance obligation The Company generates revenue from consulting services, licensing agreements and testing of cannabis and hemp products for medicinal and adult-use consumption. The Company accounts for a contract after it has been approved by all parties to the arrangement, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company evaluates the services promised in each contract at inception to determine whether the contract should be accounted for as having one or more performance obligations. The Company’s services included in its contracts are distinct from one another. The Company determines the transaction price for each contract based on the consideration it expects to receive for the distinct services being provided under the contract. The Company recognizes revenue as performance obligations are satisfied and the customer obtains control of the services provided. In determining when performance obligations are satisfied, the Company considers factors such as contract terms, payment terms and whether there is an alternative future use of the service. The Company recognizes revenue from testing services upon delivery of its testing results to the client. Customer orders for testing services are generally completed within two weeks of receiving the order. Consulting engagements may vary in length and scope, but will generally include the review and/or preparation of regulatory filings, business plans and financial models, operating plans, and technology support to customers within the same industry. Revenue from consulting services is recognized upon completion of deliverables as outlined in the consulting agreement. The Company recognizes revenue from right of use license agreements upon transfer of control of the functional intellectual property. In certain licensing agreements, the Company may receive royalty revenues based upon performance metrics which are recognized as earned over time.
Foreign Currency Translation	Foreign Currency Translation The functional currency of the Company’s subsidiary in Canada is the Canadian Dollar. The subsidiary’s assets and liabilities have been translated to U.S. Dollars using the exchange rates in effect at the balance sheet dates. Statements of operations amounts have been translated using the average exchange rate for each period. Resulting gains or losses from translating foreign currency financial statements are recorded as other comprehensive income (loss).
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company has adopted the guidance under ASC Topic 820 for financial instruments measured on a fair value on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic loss per share is computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period. There were 24,753,819 and 11,713,103 potentially dilutive common shares outstanding as of March 31, 2019 and 2018, respectively. Because of the net losses incurred during the six months ended March 31, 2019 and 2018, the impacts of dilutive instruments would have been anti-dilutive for the period presented and have been excluded from the diluted loss per share calculations.
Accounting Pronouncements	Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In January 2017, the FASB issued ASU 2017-04, “ Intangibles—Goodwill and Other (Topic 350), Simplifying the Test for Goodwill Impairment”. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Mar. 31, 2019
Investments, All Other Investments [Abstract]
Schedule of Assets and Liabilities Measured in Fair Value	The following table sets forth by level with the fair value hierarchy the Company’s financial assets and liabilities measured at fair value on Level 1 Level 2 Level 3 Total Liabilities Derivative financial instruments $ - $ - $ 2,102,387 $ 2,102,387 The following table sets forth by level with the fair value hierarchy the Company’s financial assets and liabilities measured at fair value on September 31, 2018: Level 1 Level 2 Level 3 Total Liabilities Derivative financial instruments $ - $ - $ 1,181,278 $ 1,181,278

Leases (Tables)

Leases (Tables)	6 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Schedule of Future Minimum Lease Payments of Lease Liabilities	The future minimum lease payments of lease liabilities as of March 31, 2019, are as follows: Year ended March 31, Operating Leases Financing Leases 2019 662,673 $ 404.795 2020 784,958 354,898 2021 525,852 340,025 2022 489,392 181,372 2023 323,356 204,812 Thereafter 27,911 4,977 Total lease payments 2,814,142 1,490,879 Less: Payments Made (225,192 ) (196,035 ) Total Lease Liabilities $ 2,478,950 $ 1,294,845

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The components of intangible assets as of March 31, 2019 and September 30, 2018 consist of: March 31, 2019 September 30, 2018 Customer list $ 849,458 $ 865,672 License 503,000 503,000 Favorable lease 3,100 3,100 Domains & Websites 49,448 49,690 Non-compete agreements 181,538 184,563 Assembled Workforce 50,750 50,750 Intellectual Property 332,868 342,610 Total 1,970,162 1,999,385 Accumulated amortization (506,945 ) (318,815 ) Net value $ 1,463,217 $ 1,680,570
Schedule of Future Amortization on Intangible Assets	The Company estimates amortization to be recorded on existing intangible assets through the year ended September 30, 2030 to be: Amortization 2019 $ 193,959 2020 346,656 2021 307,469 2022 238,289 2023 197,765 2024 124,847 2025 44,097 2026 2,317 2027 2,317 2028 2,317 2029 2,317 2030 868 Total $ 1,463,217

Concentration of Credit Risk (T

Concentration of Credit Risk (Tables)	6 Months Ended
	Mar. 31, 2019
Risks and Uncertainties [Abstract]
Schedule of Allowance for Accounts Receivable	As of March 31, 2019, the Company had total accounts receivable net of allowances of $122,783. Three clients comprised a total of 36% of this balance as follows: Balance Percent of Total Customer 1 $ 180,000 32 % Customer 2 29,063 5 % Customer 3 22,740 4 % All others 325,034 58 % Total 556,837 100 % Allowance for doubtful accounts (434,054 ) Net accounts receivable $ 122,783 As of September 30, 2018, the Company had total accounts receivable, net of allowances, of $234,178. Three separate clients comprised a total of 36% of this balance as follows: Balance Percent of Total Customer 1 $ 180,000 27 % Customer 2 34,268 5 % Customer 3 27,317 4 % All others 427,680 64 % Total 669,265 100 % Allowance for doubtful accounts (417,610 ) Net accounts receivable $ 251,655

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Estimated Life of Property and Equipment	The estimated useful lives of depreciable assets are: Estimated Useful Lives Building 39 years Laboratory and Computer Equipment 5 years Furniture and Fixtures 7 years Software 3 years Domains 15 years
Schedule of Property and Equipment	The Company’s property and equipment consisted of the following as of March 31, 2019 and September 30, 2018: March 31, 2019 September 30, 2018 Assets Not-In-Service $ - $ 455,540 Capital Assets 1,287,091 535,095 Land 212,550 212,550 Buildings & Real Estate 941,857 937,450 Furniture and Equipment 187,602 189,459 Laboratory Equipment 2,651,312 2,468,141 Software 73,908 63,913 Leasehold Improvements 582,695 303,331 Vehicles 83,915 83,915 Total 6,020,931 5,249,394 Accumulated depreciation (1,127,091 ) (644,291 ) Net value $ 4,893,839 $ 4,605,103

Loans Payable (Tables)

Loans Payable (Tables)	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of Loans Payable	The Company had the following loans payable outstanding as of March 31, 2019 and September 30, 2018: March 31, 2019 September 30, 2018 On March 16, 2017, the Company executed notes payable for the purchase of three vehicles. The notes carry interest at 6.637% annually and mature on March 31, 2023. 53,476 60,477 On September 6, 2017, the Company entered into a note payable totaling $1,000,000 for the purchase of an outstanding note receivable. The note carries interest at 8% annually and is due on July 6, 2018. - 500,000 On June 28, 2018, the Company executed a note payable for $650,000 for the purchase of the building at 14775 SW 74 th 634,617 646,231 On July 5, 2018, the Company executed a note payable for $750,000 for the asset purchase of MRX Labs. The note carries interest at 8% annually and is due on January 5, 2019. 750,000 750,000 1,438,093 1,956,708 Less: unamortized original issue discounts - (119,000 ) Total loans payable 1,438,093 1,837,708 Less: current portion of loans payable 786,729 643,627 Long-term portion of loans payable $ 651,364 $ 1,193,781

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	The following table summarizes all convertible notes outstanding as of March 31, 2019: Holder Issue Date Due Date Principal Unamortized Debt Discount Carrying Value Accrued Interest Noteholder 2 7/2/18 10/1/18 220,000 - 220,000 13,116 Noteholder 3 7/2/18 10/1/18 220,000 - 220,000 13,116 Noteholder 4 8/1/18 1/1/19 330,000 - 330,000 17,504 Noteholder 5 8/29/18 2/28/19 222,222 - 222,222 6,514 Noteholder 6 9/6/18 9/6/19 125,000 (37,887 ) 87,113 7,055 Noteholder 3 9/13/18 3/11/19 435,000 - 435,000 - Noteholder 7 9/17/18 9/17/19 62,500 (26,327 ) 36,173 3,339 Noteholder 4 10/2/18 1/1/19 220,000 - 220,000 8,679 Noteholder 8 11/15/18 11/15/19 222,600 (139,659 ) 82,941 6,635 Noteholder 9 12/27/18 12/27/19 105,000 (78,248 ) 26,753 2,140 Noteholder 9 12/27/18 12/27/19 131,250 (111,832 ) 19,418 2,186 Noteholder 8 11/15/18 11/15/19 265,000 (224,168 ) 40,832 3,195 Noteholder 9 131,250 (113,990 ) 17,260 1,553 Noteholder 11 580,537 (59,930 ) 520,607 8,112 Noteholder 10 4/24/18 4/24/19 500,000 - 500,000 - $ 3,770,359 $ (792,040 ) $ 2,978,319 $ 93,144 The following table summarizes all convertible notes outstanding as of September 30, 2018: Holder Issue Date Due Date Principal Unamortized Debt Discount Carrying Value Accrued Interest Noteholder 2 7/2/18 10/1/18 220,000 (220 ) 219,780 4,340 Noteholder 3 7/2/18 10/1/18 220,000 (220 ) 219,780 4,340 Noteholder 4 8/1/18 10/1/18 330,000 (492 ) 329,508 - Noteholder 1 8/14/18 8/14/19 167,100 (13,591 ) 153,509 2,839 Noteholder 5 8/29/18 2/28/19 222,222 (78,670 ) 143,552 - Noteholder 6 9/6/18 9/6/19 125,000 (89,921 ) 35,079 - Noteholder 3 9/13/18 3/11/19 585,000 (513,062 ) 71,938 - Noteholder 7 9/17/18 9/17/19 62,500 (57,381 ) 5,119 - Noteholder 10 4/24/18 4/24/19 500,000 0 500,000 - $ 2,431,822 $ (753,557 ) $ 1,678,265 $ 11,519

Convertible Debentures (Tables)

Convertible Debentures (Tables)	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of Fair Value Assumptions of Warrants	Expected term of options granted 2 years Expected volatility 223 % Risk-free interest rate 2.49 % Expected dividend yield 0 % Expected term of options granted 2 years Expected volatility 211 - 223 % Risk-free interest rate 2.09 - 2.25 % Expected dividend yield 0 %

Derivative Liability (Tables)

Derivative Liability (Tables)	6 Months Ended
	Mar. 31, 2019
Derivative Liability [Abstract]
Schedule of Derivative Liabilities	The following table summarizes the derivative liabilities included in the balance sheet at March 31, 2019: Fair Value of Derivative Liabilities: Balance, September 30, 2018 $ 1,181,278 Initial measurement of derivative liabilities 1,145,140 Change in fair market value (224,021 ) Write off due to conversion - Balance, March 31, 2019 $ 2,102,387
Summary of Gain (Loss) on Derivative Liability	The following table summarizes the gain (loss) on derivative liability included in the income statement for the six months ended March 31, 2019 and 2018, respectively. March 31, 2018 2017 Day one loss due to derivatives on convertible debt $ (780,678 ) $ (352,206 ) Change in fair value of derivatives 224,021 160,928 Total derivative gain (loss) $ (556,647 ) $ (191,278 )

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	6 Months Ended
	Mar. 31, 2019
Stock Options And Warrants
Summary of Stock Option and Warrant Activity	The following table summarizes all stock option and warrant activity for the six months ended March 31, 2019: Shares Weighted-Average Outstanding, September 30, 2018 4,638,050 $ 0.784 Granted 646,920 0.610 Exercised - Forfeited - - Expired - - Outstanding, March 31, 2019 5,284,970 $ 0.764
Schedule of Outstanding and Exercisable Options and Warrants	The following table discloses information regarding outstanding and exercisable options and warrants at March 31, 2019: Outstanding Exercisable Exercise Prices Number of Option Shares Weighted Weighted Average Number of Option Shares Weighted Average Exercise Price $ 0.400 110,000 $ 0.400 2.38 110,000 $ 0.400 $ 0.420 330,000 $ 0.420 4.80 330,000 $ 0.420 $ 0.500 165,000 $ 0.500 2.45 162,500 $ 0.500 $ 0.600 627,220 $ 0.600 0.87 627,220 $ 0.600 $ 0.650 145,000 $ 0.650 3.57 36,250 $ 0.650 $ 0.800 3,482,750 $ 0.800 2.19 3,095,250 $ 0.800 $ 0.850 100,000 $ 0.850 4.05 - $ 0.850 $ 1.050 25,000 $ 1.050 4.55 - $ 1.050 $ 1.260 220,000 $ 1.260 3.25 110,000 $ 1.260 $ 1.300 10,000 $ 1.300 2.56 7,500 $ 1.300 $ 1.386 60,000 $ 1.386 3.25 30,000 $ 1.386 $ 1.666 10,000 $ 1.666 3.34 5,000 1.666 Total 5,284,970 $ 0.783 2.82 4,513,720 $ 0.764
Schedule of Stock Option Granted Assumptions	The assumptions used in these calculations are summarized as follows: March 31, 2019 Expected term of options granted 1.1 to 5.0 years Expected volatility 102.63 to 122.49 % Risk-free interest rate 2.57 to 2.67 % Expected dividend yield 0 %

Organization, Basis of Presen_3

Organization, Basis of Presentation and Significant Accounting Policies (Details Narrative)	6 Months Ended
	Mar. 31, 2019Laboratoriesshares	Mar. 31, 2018shares
Dilutive common shares outstanding | shares	24,753,819	11,713,103
Oregon [Member]
Number of operating laboratories	2
Canada [Member]
Number of operating laboratories	1
Florida [Member]
Number of operating laboratories	2
Colorado [Member]
Number of operating laboratories	1
Canada [Member]
Number of operating laboratories	1
EVIO Labs Portland [Member] | Oregon [Member]
Ownership percentage	100.00%
EVIO Labs Medford [Member] | Oregon [Member]
Ownership percentage	80.00%
BCC Licensed and ISO 17025 Accredited Laboratory [Member] | Canada [Member]
Ownership percentage	90.00%
GMP Certified Laboratory [Member] | Canada [Member]
Ownership percentage	50.00%

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured in Fair Value (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Derivative financial instruments	$ 2,102,387	$ 1,181,278
Level 1 [Member]
Derivative financial instruments
Level 2 [Member]
Derivative financial instruments
Level 3 [Member]
Derivative financial instruments	$ 2,102,387	$ 1,181,278

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2019	Oct. 02, 2018	Sep. 30, 2018
Leases [Abstract]
Lease expirations description	These commitments have remaining non-cancelable lease terms, with lease expirations which range from 2020 to 2024.
Right of use assets	$ 2,667,715	$ 2,667,715
Lease Liability	$ 2,716,047	$ 2,828,361

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments of Lease Liabilities (Details)	Mar. 31, 2019USD ($)
Leases [Abstract]
Operating Leases, Year ended March 31, 2019	$ 662,673
Operating Leases, Year ended March 31, 2020	784,958
Operating Leases, Year ended March 31, 2021	525,852
Operating Leases, Year ended March 31, 2022	489,392
Operating Leases, Year ended March 31, 2023	323,356
Operating Leases, Thereafter	27,911
Operating Leases, Total lease payments	2,814,142
Operating Leases, Less: Payments Made	(225,192)
Operating Leases, Total Lease Liabilities	2,478,950
Financing Leases, Year ended March 31, 2019	404,795
Financing Leases, Year ended March 31, 2020	354,898
Financing Leases, Year ended March 31, 2021	340,025
Financing Leases, Year ended March 31, 2022	181,372
Financing Leases, Year ended March 31, 2023	204,812
Financing Leases, Thereafter	4,977
Financing Leases, Total lease payments	1,490,879
Financing Leases, Less: Payments Made	(196,035)
Financing Leases, Total Lease Liabilities	$ 1,294,845

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Intangible assets, gross	$ 1,970,162	$ 1,999,385
Accumulated amortization	(506,944)	(318,816)
Net value	1,463,217	1,680,570
Customer List [Member]
Intangible assets, gross	849,458	865,672
License [Member]
Intangible assets, gross	503,000	503,000
Favorable Lease [Member]
Intangible assets, gross	3,100	3,100
Domains & Websites [Member]
Intangible assets, gross	49,448	49,690
Noncompete Agreements [Member]
Intangible assets, gross	181,538	184,563
Assembled Workforce [Member]
Intangible assets, gross	50,750	50,750
Intellectual Property [Member]
Intangible assets, gross	$ 332,868	$ 342,610

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Future Amortization on Intangible Assets (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 193,959
2020	346,656
2021	307,469
2022	238,289
2023	197,765
2024	124,847
2025	44,097
2026	2,317
2027	2,317
2028	2,317
2029	2,317
2030	868
Total	$ 1,463,217	$ 1,680,570

Concentration of Credit Risk (D

Concentration of Credit Risk (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Mar. 31, 2019	Sep. 30, 2018
Cash insured by Federal Deposit Insurance Corporation	$ 250,000
Notes receivable, net	1,300,000	$ 1,300,000
Accounts receivable, net	$ 122,783	$ 251,655
Credit Concentration Risk [Member]
Concentration risk percentage	100.00%	100.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration risk percentage	32.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration risk percentage	36.00%	36.00%

Concentration of Credit Risk -

Concentration of Credit Risk - Schedule of Allowance for Accounts Receivable (Details) - USD ($)	6 Months Ended	12 Months Ended
	Mar. 31, 2019	Sep. 30, 2018
Gross accounts receivable	$ 556,837	$ 669,265
Allowance for doubtful accounts	(445,887)	(414,475)
Net accounts receivable	$ 122,783	$ 251,655
Credit Concentration Risk [Member]
Concentration of risk percentage	100.00%	100.00%
Customer 1 [Member]
Gross accounts receivable	$ 180,000	$ 180,000
Customer 1 [Member] | Credit Concentration Risk [Member]
Concentration of risk percentage	32.00%	27.00%
Customer 2 [Member]
Gross accounts receivable	$ 29,063	$ 34,268
Customer 2 [Member] | Credit Concentration Risk [Member]
Concentration of risk percentage	5.00%	5.00%
Customer 3 [Member]
Gross accounts receivable	$ 22,740	$ 27,317
Customer 3 [Member] | Credit Concentration Risk [Member]
Concentration of risk percentage	4.00%	4.00%
All Others [Member]
Gross accounts receivable	$ 325,034	$ 427,680
All Others [Member] | Credit Concentration Risk [Member]
Concentration of risk percentage	58.00%	64.00%

Property and Equipment (Details

Property and Equipment (Details Narrative)	6 Months Ended
	Mar. 31, 2019USD ($)
Property, Plant and Equipment [Abstract]
Capitalized equipment	$ 738,141
Depreciation expense	$ 230,454

Property and Equipment - Schedu

Property and Equipment - Schedule of Estimated Life of Property and Equipment (Details)	6 Months Ended
	Mar. 31, 2019
Building [Member]
Property and equipment, estimated useful life	39 years
Laboratory and Computer Equipment [Member]
Property and equipment, estimated useful life	5 years
Furniture and Fixtures [Member]
Property and equipment, estimated useful life	7 years
Software [Member]
Property and equipment, estimated useful life	3 years
Domains [Member]
Property and equipment, estimated useful life	15 years

Property and Equipment - Sche_2

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Property and equipment gross	$ 6,020,931	$ 5,249,394
Accumulated depreciation	(897,746)	(520,437)
Net value	3,623,541	3,525,772
Assets Not-In-Service [Member]
Property and equipment gross		455,540
Capital Assets [Member]
Property and equipment gross	1,287,091	535,095
Land [Member]
Property and equipment gross	212,550	212,550
Buildings & Real Estate [Member]
Property and equipment gross	941,857	937,450
Furniture and Equipment [Member]
Property and equipment gross	187,602	189,459
Laboratory Equipment [Member]
Property and equipment gross	2,651,312	2,468,141
Software [Member]
Property and equipment gross	73,908	63,913
Leasehold Improvements [Member]
Property and equipment gross	582,695	303,331
Vehicles [Member]
Property and equipment gross	$ 83,915	$ 83,915

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018
Loan received from related party	$ 199,040
Repayments of related party debt	27,151	$ 176,528
Unamortized debt discount	792,040		$ 753,557
Keystone Labs [Member]
Loan received from related party	119,937
Repayments of related party debt	25,886
Due to related party	153,177		25,886
Chief Operating Officer [Member]
Loan received from related party	15,000
Repayments of related party debt	1,040
Due to related party	13,960		0
Sara Lausmann [Member] | Oregon Analytical Services, LLC [Member]
Repayments of related party debt	9,000
Due to related party	$ 571,299		580,299
Interest rate	5.00%
Accrued interest	$ 93,653		79,295
Anthony Smith [Member]
Repayments of related party debt	12,000
Due to related party	$ 224,000		236,000
Interest rate	5.00%
Accrued interest	$ 36,696		30,960
Anthony Smith [Member] | Smith Scientific Industries [Member]
Purchase percentage	80.00%
Henry Grimmett [Member] | Greenhaus Analytical Services, LLC [Member] | Interest 0% [Member]
Due to related party	$ 113,554		117,412
Interest rate	0.00%
Notes payable	$ 3,859
Repayment of debt quarterly	25,000
Henry Grimmett [Member] | Greenhaus Analytical Services, LLC [Member] | Interest 6% [Member]
Due to related party	$ 340,000		340,000
Interest rate	6.00%
Accrued interest	$ 50,078		39,905
Notes payable	$ 340,000
Maturity date	Oct. 16, 2020
Unamortized debt discount	$ 39,302		$ 51,971

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018
Common shares issued for services, value	$ 53,000	$ 128,400	$ 38,252	$ 241,157
Common shares issued for conversion of convertible debentures, value		$ 388,000
Incentive plan expense					$ 395,850	$ 1,234,415
Common stock, shares issued	27,094,744		16,068,505		27,094,744	16,068,505	23,255,409
Common stock, shares outstanding	27,094,744		16,068,505		27,094,744	16,068,505	23,255,409
Common Stock [Member]
Conversion of stock, shares converted					507,500	700,000
Common shares issued for services					350,000	207,750
Common shares issued for services, value					$ 181,400	$ 254,720
Common shares issued for cash					400,000	1,270,000
Common shares issued for cash, value					$ 186,000	$ 508,000
Common shares stock subscription	1,015,000				1,015,000
Common shares stock subscription, value	$ 406,000				$ 406,000
Common shares issued for employee equity incentive plan					87,500	57,000
Common shares issued for employee equity incentive plan, value					$ 55,375	$ 75,755
Common shares issued for conversion of convertible notes payable					779,808	1,869,650
Common shares issued for conversion of convertible notes payable, value					$ 317,100	$ 703,215
Common shares issued for conversion of convertible debentures					669,362
Common shares issued for conversion of convertible debentures, value					$ 388,000
Common shares issued for conversion of interest payable					10,163
Common shares issued for conversion of interest payable, value					$ 2,988
Common shares issued for debt issuance costs					20,000	670,271
Common shares issued for debt issuance costs, value					$ 11,760	$ 1,414,907
Incentive plan expense						$ 166,647
Common shares issued for conversion of accrued interest						74,412
Common shares issued for conversion of accrued interest, value						$ 27,270
Common Stock [Member] | Accounts Payable [Member]
Common shares issued for settlement of debt						37,500
Common shares issued for settlement of debt, value						$ 15,000
Common Stock [Member] | Non-Convertible Debt [Member]
Common shares issued for settlement of debt						324,000
Common shares issued for settlement of debt, value						$ 122,157
Common Stock [Member] | Non-Convertible Related Party Debt [Member]
Common shares issued for settlement of debt						125,000
Common shares issued for settlement of debt, value						$ 50,000
Series A Preferred Stock [Member]
Preferred stock, shares issued	0		0		0	0
Preferred stock, shares outstanding	0		0		0	0
Series B Preferred Stock [Member]
Preferred stock, shares issued	5,000,000		5,000,000		5,000,000	5,000,000	5,000,000
Preferred stock, shares outstanding	5,000,000		5,000,000		5,000,000	5,000,000	5,000,000
Preferred stock, shares designated	5,000,000		5,000,000		5,000,000	5,000,000	5,000,000
Preferred stock, shares par value	$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Convertible preferred stock shares converted	1				1
Common shares issued for services
Common shares issued for services, value
Common shares issued for conversion of convertible debentures
Common shares issued for conversion of convertible debentures, value
Series C Preferred Stock [Member]
Preferred stock, shares issued	500,000		500,000		500,000	500,000	500,000
Preferred stock, shares outstanding	500,000		500,000		500,000	500,000	500,000
Preferred stock, shares designated	500,000		500,000		500,000	500,000	500,000
Preferred stock, shares par value	$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Convertible preferred stock shares converted	5				5
Common shares issued for services
Common shares issued for services, value
Common shares issued for conversion of convertible debentures
Common shares issued for conversion of convertible debentures, value
Series D Preferred Stock [Member]
Preferred stock, shares issued	349,500		552,500		349,500	552,500	552,500
Preferred stock, shares outstanding	349,500		552,500		349,500	552,500	552,500
Preferred stock, shares designated	1,000,000		1,000,000		1,000,000	1,000,000	1,000,000
Preferred stock, shares par value	$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001
Convertible preferred stock shares converted	2.5				2.5
Conversion of stock, shares converted					203,000	280,000
Common shares issued for services
Common shares issued for services, value
Common shares issued for conversion of convertible debentures
Common shares issued for conversion of convertible debentures, value

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Loans Payable [Member]
Accrued interest	$ 45,834	$ 47,767

Loans Payable - Schedule of Loa

Loans Payable - Schedule of Loans Payable Outstanding (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Notes payable	$ 1,438,093	$ 1,956,708
Less: unamortized original issue discounts		(119,000)
Total loans payable	1,438,093	1,837,708
Less: current portion of loans payable	786,727	643,927
Long-term portion of loans payable	651,365	1,193,781
Notes Payable 1 [Member]
Notes payable	53,476	60,477
Notes Payable 2 [Member]
Notes payable		500,000
Notes Payable 3 [Member]
Notes payable	634,617	646,231
Notes Payable 4 [Member]
Notes payable	$ 750,000	$ 750,000

Loans Payable - Schedule of L_2

Loans Payable - Schedule of Loans Payable Outstanding (Details) (Parenthetical) - USD ($)	Jul. 05, 2018	Jun. 28, 2018	Sep. 06, 2017	Mar. 16, 2017	Mar. 31, 2019	Sep. 30, 2018
Debt instrument principal amount					$ 3,770,359	$ 2,431,822
Notes Payable 1 [Member]
Debt instrument interest rate				6.637%
Debt instrument maturity date				Mar. 31, 2023
Notes Payable 2 [Member]
Debt instrument interest rate			8.00%
Debt instrument maturity date			Jul. 6, 2018
Debt instrument principal amount			$ 1,000,000
Notes Payable 3 [Member]
Debt instrument interest rate		8.00%
Debt instrument maturity date		Jun. 28, 2021
Debt instrument principal amount		$ 650,000
Notes Payable 4 [Member]
Debt instrument interest rate	8.00%
Debt instrument maturity date	Jan. 5, 2019
Debt instrument principal amount	$ 750,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	Feb. 11, 2019USD ($)	Feb. 08, 2019USD ($)TradingDays	Feb. 05, 2019USD ($)	Feb. 04, 2019USD ($)TradingDays	Jan. 14, 2019USD ($)TradingDays	Dec. 27, 2018USD ($)TradingDays	Nov. 15, 2018USD ($)$ / shares	Nov. 15, 2018USD ($)$ / shares	Oct. 02, 2018USD ($)$ / shares	Sep. 17, 2018USD ($)TradingDays	Sep. 06, 2018USD ($)$ / shares	Aug. 29, 2018USD ($)$ / shares	Aug. 01, 2018USD ($)$ / shares	Jul. 02, 2018USD ($)$ / shares	Apr. 24, 2018USD ($)TradingDays$ / shares	Aug. 14, 2017USD ($)TradingDays	Mar. 31, 2019USD ($)	Sep. 30, 2018USD ($)shares
Debt instrument face amount																	$ 3,770,359	$ 2,431,822
Noteholder 1 [Member]
Debt instrument face amount																$ 275,600	0	$ 167,100
Original issue discount																15,600
Cash paid to third parties																10,000
Cash proceeds from convertible promissory note																$ 250,000
Debt instrument interest rate																8.00%
Debt instrument maturity date																Aug. 14, 2018		Aug. 14, 2019
Debt instrument description																The Note is convertible into the Company's common stock commencing 180 days from the date of issuance at a conversion price equal to 75% of the lowest trade price of the Company's common stock for the fifteen prior trading days including the date of conversion.
Debt instrument threshold percentage																75.00%
Debt instrument trading days | TradingDays																15
Debt conversion principal amount converted																		$ 167,100
Debt conversion principal amount converted, shares | shares																		479,848
Debt conversion interest amount converted																		$ 2,988
Debt conversion interest amount converted, shares | shares																		10,163
Accrued interest																	0	$ 2,839
Noteholder 2 [Member]
Debt instrument face amount														$ 220,000			$ 220,000	$ 220,000
Original issue discount														20,000
Cash paid to third parties														17,000
Cash proceeds from convertible promissory note														$ 183,000
Debt instrument interest rate														8.00%
Debt instrument maturity date														Oct. 1, 2018			Oct. 1, 2018	Oct. 1, 2018
Accrued interest																	$ 13,116	$ 4,340
Conversion price per share | $ / shares														$ 0.60
Noteholder 3 [Member]
Debt instrument face amount														$ 220,000			$ 220,000	$ 220,000
Original issue discount														20,000
Cash proceeds from convertible promissory note														$ 200,000
Debt instrument interest rate														8.00%
Debt instrument maturity date														Oct. 1, 2018			Oct. 1, 2018	Oct. 1, 2018
Accrued interest																	$ 13,116	$ 4,340
Conversion price per share | $ / shares														$ 0.60
Noteholder 3 [Member]
Debt instrument face amount										$ 585,000							$ 435,000	$ 585,000
Original issue discount										$ 35,348
Debt instrument interest rate										0.00%
Debt instrument maturity date																	Mar. 11, 2019	Mar. 11, 2019
Debt instrument description										The new convertible note payable carries an interest rate of 0% per annum is convertible into common stock of the Company at the option of the noteholder immediately at 80% of the lowest volume weighted average price of the Company's common stock in the preceding 20 trading days.
Debt instrument threshold percentage										80.00%
Debt instrument trading days | TradingDays										20
Accrued interest																	$ 0	$ 0
Noteholder 3 [Member] | Palliatech [Member]
Debt instrument face amount										$ 549,652
Noteholder 4 [Member]
Debt instrument face amount													$ 330,000				$ 330,000	$ 330,000
Original issue discount													30,000
Cash proceeds from convertible promissory note													$ 300,000
Debt instrument interest rate													8.00%
Debt instrument maturity date													Oct. 1, 2018				Jan. 1, 2019	Oct. 1, 2018
Accrued interest																	$ 17,504	$ 10,994
Conversion price per share | $ / shares													$ 0.60
Noteholder 4 [Member]
Debt instrument face amount									$ 220,000								$ 220,000
Original issue discount									20,000
Cash proceeds from convertible promissory note									$ 200,000
Debt instrument interest rate									8.00%
Debt instrument maturity date									Jan. 1, 2019								Jan. 1, 2019
Accrued interest																	$ 8,679
Conversion price per share | $ / shares									$ 0.60
Noteholder 5 [Member]
Debt instrument face amount												$ 222,222					$ 222,222	$ 222,222
Original issue discount												22,222
Cash paid to third parties												5,500
Cash proceeds from convertible promissory note												$ 194,500
Debt instrument interest rate												5.00%
Debt instrument maturity date												Feb. 28, 2019					Feb. 28, 2019	Feb. 28, 2019
Accrued interest																	$ 3,775	$ 0
Conversion price per share | $ / shares												$ 0.70
Noteholder 6 [Member]
Debt instrument face amount											$ 125,000						$ 125,000	$ 125,000
Original issue discount											15,000
Cash proceeds from convertible promissory note											$ 110,000
Debt instrument interest rate											10.00%
Debt instrument maturity date											Sep. 6, 2019						Sep. 6, 2019	Sep. 6, 2019
Accrued interest																	$ 7,055	$ 0
Conversion price per share | $ / shares											$ 0.50
Noteholder 7 [Member]
Debt instrument face amount											$ 62,500						$ 62,500	$ 62,500
Original issue discount											6,250
Cash proceeds from convertible promissory note											$ 56,250
Debt instrument interest rate											10.00%
Debt instrument maturity date											Sep. 6, 2019						Sep. 17, 2019	Sep. 17, 2019
Accrued interest																	$ 3,339	$ 0
Conversion price per share | $ / shares											$ 0.50
Noteholder 8 [Member]
Debt instrument face amount							$ 222,600	$ 222,600									$ 222,600
Original issue discount							$ 12,600	12,600
Cash proceeds from convertible promissory note								$ 210,000
Debt instrument interest rate							8.00%	8.00%
Debt instrument maturity date							Nov. 15, 2019	Nov. 15, 2019									Nov. 15, 2019
Accrued interest																	$ 6,635
Conversion price per share | $ / shares							$ 0.55	$ 0.55
Noteholder 8 [Member]
Debt instrument face amount				$ 265,000													$ 265,000
Original issue discount				15,000
Cash paid to third parties				10,000
Cash proceeds from convertible promissory note				$ 240,000
Debt instrument interest rate				8.00%
Debt instrument maturity date				Feb. 4, 2020													Nov. 15, 2019
Debt instrument description				The convertible note payable carries interest at a rate of 8% per annum, is due on February 4, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company's common stock in the preceding 15 trading days.
Debt instrument threshold percentage				35.00%
Debt instrument trading days | TradingDays				15
Accrued interest																	$ 3,195
Noteholder 9 [Member]
Debt instrument face amount						$ 105,000											$ 105,000
Debt instrument interest rate						8.00%
Debt instrument maturity date						Dec. 27, 2019											Dec. 27, 2019
Debt instrument description						The Note is convertible into the Company's common stock commencing 180 days from the date of issuance at a conversion price equal to 65% of the lowest trade price of the Company's common stock for the fifteen prior trading days including the date of conversion.
Debt instrument threshold percentage						65.00%
Debt instrument trading days | TradingDays						15
Accrued interest																	$ 2,140
Noteholder 9 [Member]
Debt instrument face amount			$ 131,250		$ 131,250												$ 131,250
Cash paid to third parties					6,250
Cash proceeds from convertible promissory note					$ 125,000
Debt instrument interest rate					8.00%
Debt instrument maturity date			Feb. 5, 2020		Jan. 14, 2020												Dec. 27, 2019
Debt instrument description					The convertible note payable carries interest at a rate of 8% per annum, is due on January 14, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company's common stock in the preceding 15 trading days.
Debt instrument threshold percentage					35.00%
Debt instrument trading days | TradingDays					15
Accrued interest																	$ 2,186
Noteholder 9 [Member]
Debt instrument face amount	$ 131,250			$ 131,250													131,250
Cash paid to third parties				6,250
Cash proceeds from convertible promissory note				$ 125,000
Debt instrument interest rate				8.00%
Debt instrument maturity date	Feb. 11, 2020			Feb. 4, 2020
Debt instrument description				The convertible note payable carries interest at a rate of 8% per annum, is due on February 4, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 35% discount from the lowest trading price of the Company's common stock in the preceding 15 trading days.
Debt instrument threshold percentage				35.00%
Debt instrument trading days | TradingDays				15
Accrued interest																	1,553
Noteholder 10 [Member]
Debt instrument face amount															$ 500,000		$ 500,000	$ 500,000
Debt instrument maturity date															Apr. 24, 2019		Apr. 24, 2019	Apr. 24, 2019
Debt instrument description															In the event the average lowest trading price of the Company's common stock during the five days prior to maturity is less than $1.25 per share, the Company will pay the noteholder the difference between $1.25 and the average lowest trading price during the preceding five days per share converted in cash.
Debt instrument trading days | TradingDays															5
Accrued interest																	$ 0	$ 0
Conversion price per share | $ / shares															$ 1.25
Percentage of asset exchange															100.00%
Debt instrument trading price | $ / shares															$ 1.25
Noteholder 11 [Member]
Debt instrument face amount		$ 580,537															580,537
Debt instrument interest rate		10.00%
Debt instrument maturity date		Feb. 8, 2020
Debt instrument description		The new convertible note payable carries an interest rate of 10% per annum, with one year interest guaranteed, is due on February 8, 2020 and is convertible into common stock of the Company at the option of the noteholder six months after issuance at a rate equal to a 30% discount from the lowest trading price of the Company's common stock in the preceding 15 trading days.
Debt instrument threshold percentage		30.00%
Debt instrument trading days | TradingDays		15
Accrued interest																	$ 8,112

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)

Feb. 11, 2019

Feb. 08, 2019

Feb. 05, 2019

Feb. 04, 2019

Jan. 14, 2019

Dec. 27, 2018

Nov. 15, 2018

Nov. 15, 2018

Oct. 02, 2018

Sep. 06, 2018

Aug. 29, 2018

Aug. 01, 2018

Jul. 02, 2018

Apr. 24, 2018

Aug. 14, 2017

Mar. 31, 2019

Sep. 30, 2018

Sep. 17, 2018

Principal

$ 3,770,359

$ 2,431,822

Unamortized debt discount

(792,040)

(753,557)

Carrying value

2,978,319

1,678,265

Accrued interest

$ 767,524

$ 416,459

Noteholder 2 [Member]

Issue date

Jul. 2, 2018

Jul. 2, 2018

Due date

Oct. 1, 2018

Oct. 1, 2018

Oct. 1, 2018

Principal

$ 220,000

$ 220,000

$ 220,000

Unamortized debt discount

(220)

Carrying value

220,000

219,780

Accrued interest

$ 13,116

$ 4,340

Noteholder 3 [Member]

Issue date

Jul. 2, 2018

Jul. 2, 2018

Due date

Oct. 1, 2018

Oct. 1, 2018

Oct. 1, 2018

Principal

$ 220,000

$ 220,000

$ 220,000

Unamortized debt discount

(220)

Carrying value

220,000

219,780

Accrued interest

$ 13,116

$ 4,340

Noteholder 4 [Member]

Issue date

Aug. 1, 2018

Aug. 1, 2018

Due date

Oct. 1, 2018

Jan. 1, 2019

Oct. 1, 2018

Principal

$ 330,000

$ 330,000

$ 330,000

Unamortized debt discount

(492)

Carrying value

330,000

329,508

Accrued interest

$ 17,504

Noteholder 5 [Member]

Issue date

Aug. 29, 2018

Aug. 29, 2018

Due date

Feb. 28, 2019

Feb. 28, 2019

Feb. 28, 2019

Principal

$ 222,222

$ 222,222

$ 222,222

Unamortized debt discount

(78,670)

Carrying value

222,222

143,552

Accrued interest

$ 6,514

Noteholder 6 [Member]

Issue date

Sep. 6, 2018

Sep. 6, 2018

Due date

Sep. 6, 2019

Sep. 6, 2019

Sep. 6, 2019

Principal

$ 125,000

$ 125,000

$ 125,000

Unamortized debt discount

(37,887)

(89,921)

Carrying value

87,113

35,079

Accrued interest

$ 7,055

Noteholder 3 [Member]

Issue date

Sep. 13, 2018

Sep. 13, 2018

Due date

Mar. 11, 2019

Mar. 11, 2019

Principal

$ 435,000

$ 585,000

$ 585,000

Unamortized debt discount

(513,062)

Carrying value

435,000

71,938

Accrued interest

Noteholder 7 [Member]

Issue date

Sep. 17, 2018

Sep. 17, 2018

Due date

Sep. 6, 2019

Sep. 17, 2019

Sep. 17, 2019

Principal

$ 62,500

$ 62,500

$ 62,500

Unamortized debt discount

(26,327)

(57,381)

Carrying value

36,173

5,119

Accrued interest

$ 3,339

Noteholder 4 [Member]

Issue date

Oct. 2, 2018

Due date

Jan. 1, 2019

Jan. 1, 2019

Principal

$ 220,000

$ 220,000

Unamortized debt discount

Carrying value

220,000

Accrued interest

$ 8,679

Noteholder 8 [Member]

Issue date

Nov. 15, 2018

Due date

Nov. 15, 2019

Nov. 15, 2019

Nov. 15, 2019

Principal

$ 222,600

$ 222,600

$ 222,600

Unamortized debt discount

$ (184,957)

$ (184,957)

(139,659)

Carrying value

82,941

Accrued interest

$ 6,635

Noteholder 9 [Member]

Issue date

Dec. 27, 2018

Due date

Dec. 27, 2019

Dec. 27, 2019

Principal

$ 105,000

$ 105,000

Unamortized debt discount

$ (38,365)

(78,248)

Carrying value

26,753

Accrued interest

$ 2,140

Noteholder 9 [Member]

Issue date

Dec. 27, 2018

Due date

Feb. 5, 2020

Jan. 14, 2020

Dec. 27, 2019

Principal

$ 131,250

$ 131,250

$ 131,250

Unamortized debt discount

$ (14,423)

(111,832)

Carrying value

19,418

Accrued interest

$ 2,186

Noteholder 8 [Member]

Issue date

Nov. 15, 2018

Due date

Feb. 4, 2020

Nov. 15, 2019

Principal

$ 265,000

$ 265,000

Unamortized debt discount

(224,168)

Carrying value

40,832

Accrued interest

3,195

Noteholder 9 [Member]

Due date

Feb. 11, 2020

Feb. 4, 2020

Principal

$ 131,250

$ 131,250

131,250

Unamortized debt discount

(113,990)

Carrying value

17,260

Accrued interest

1,553

Noteholder 11 [Member]

Due date

Feb. 8, 2020

Principal

$ 580,537

580,537

Unamortized debt discount

(59,930)

Carrying value

520,607

Accrued interest

$ 8,112

Noteholder 10 [Member]

Issue date

Apr. 24, 2018

Apr. 24, 2018

Due date

Apr. 24, 2019

Apr. 24, 2019

Apr. 24, 2019

Principal

$ 500,000

$ 500,000

$ 500,000

Unamortized debt discount

0

Carrying value

500,000

500,000

Accrued interest

Noteholder 1 [Member]

Issue date

Aug. 14, 2018

Due date

Aug. 14, 2018

Aug. 14, 2019

Principal

$ 275,600

$ 0

$ 167,100

Unamortized debt discount

(13,591)

Carrying value

153,509

Accrued interest

$ 2,839

Convertible Debentures (Details

Convertible Debentures (Details Narrative) - USD ($)	Jan. 29, 2018	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018
Debt instrument principal amount		$ 3,770,359		$ 2,431,822
Gross proceeds from debenture issuance		971,014
Amortization of debt discount		1,951,983	$ 1,199,159
Unamortized debt discount		792,040		$ 753,557
8% Unsecured Convertible Debentures [Member]
Issuance of debentures	5,973
Debt instrument interest rate	8.00%
Debt instrument principal amount	$ 1,000
Number of warrants to issued	250
Gross proceeds from debenture issuance	$ 5,973,000
Warrants exercise price	$ 0.80
Warrant term	24 months
Debt instrument term	36 months
Debt conversion price	$ 0.60
Convertible Debentures [Member]
Debt instrument interest rate	6.00%
Debt instrument principal amount		5,183,000
Number of warrants to issued	597,300
Warrants exercise price	$ 0.60
Warrant term	2 years
Cash based issuance costs	$ 702,963
Common share value	$ 1,414,907
Additional Warrants to purchase common stock	1,265,385
Debt issuance costs	$ 3,383,255
Detachable warrants issued with convertible debentures	3,351,160
Convertible debenture converted into common stock	$ 6,957,000
Convertible debenture converted into common stock, shares	11,595,000
Total initial measurement of warrants issued with convertible debentures	$ 4,616,545
Amortization of debt discount	4,465,131	698,521
Debt discount and issuance costs	$ 6,583,000
Unamortized debt discount		3,484,269
Accrued interest		$ 446,427
Three Separate Debentures [Member]
Issuance of debentures				3
Number of warrants to issued				152,500
Gross proceeds from debenture issuance				$ 610,000
Warrants exercise price				$ 0.80
Debt conversion price				$ 0.60
Nineteen Additional Debentures [Member]
Issuance of debentures		19
Number of warrants to issued		187,000
Gross proceeds from debenture issuance		$ 374,000
Warrants exercise price		$ 0.80
Debt conversion price		$ 0.60

Convertible Debentures - Schedu

Convertible Debentures - Schedule of Fair Value Assumptions of Warrants (Details)	6 Months Ended
	Mar. 31, 2019
Expected Term of Options Granted [Member]
Warrant fair value measurement term	2 years
Expected Term of Options Granted [Member] | Detachable Warrants [Member]
Warrant fair value measurement term	2 years
Expected Volatility [Member]
Warrant fair value measurement	2.23
Expected Volatility [Member] | Detachable Warrants [Member] | Minimum [Member]
Warrant fair value measurement	2.11
Expected Volatility [Member] | Detachable Warrants [Member] | Maximum [Member]
Warrant fair value measurement	2.23
Risk Free Interest Rate [Member]
Warrant fair value measurement	0.0249
Risk Free Interest Rate [Member] | Detachable Warrants [Member] | Minimum [Member]
Warrant fair value measurement	0.0209
Risk Free Interest Rate [Member] | Detachable Warrants [Member] | Maximum [Member]
Warrant fair value measurement	0.0225
Expected Dividend Yield [Member]
Warrant fair value measurement	0
Expected Dividend Yield [Member] | Detachable Warrants [Member]
Warrant fair value measurement	0

Derivative Liability (Details N

Derivative Liability (Details Narrative)	Feb. 11, 2019USD ($)	Feb. 05, 2019USD ($)	Feb. 04, 2019USD ($)	Jan. 14, 2019USD ($)	Dec. 27, 2018USD ($)	Nov. 15, 2018USD ($)	Nov. 15, 2018USD ($)	Oct. 02, 2018USD ($)shares	Mar. 31, 2019USD ($)$ / shares	Mar. 31, 2018USD ($)	Mar. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2018USD ($)	Sep. 30, 2018USD ($)
Derivative liability									$ 2,102,387		$ 2,102,387		$ 1,181,278
Gain on derivative liability											(556,647)	$ 1,794,091
Debt instrument face amount									3,770,359		3,770,359		2,431,822
Debt instrument discount									792,040		792,040		$ 753,557
Loss on derivative fair value measurement											1,145,140
Change in fair value of derivatives									(1,409,305)	$ 1,780,769	(556,647)	$ 1,794,091
Convertible Debenture [Member]
Debt instrument face amount								$ 220,000
Debt instrument maturity date								Jan. 1, 2019
Convertible Debenture [Member] | October 17, 2020 to October 23, 2020 [Member]
Debt instrument face amount									374,000		374,000
Conversion Features [Member]
Derivative liability									$ 1,445,738		1,445,738
Change in fair value of derivatives											$ 430,636
Conversion Features [Member] | Measurement Input, Price Volatility [Member]
Derivative liability measurement input									1.10		1.10
Conversion Features [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative liability measurement input									0.0240		0.0240
Conversion Features [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Derivative liability measurement input | $ / shares									0.21		0.21
Conversion Features [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Derivative liability measurement input | $ / shares									0.31		0.31
Conversion Features [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Derivative liability measurement input term											7 months 17 days
Conversion Features [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Derivative liability measurement input term											10 months 14 days
Warrants [Member]
Derivative liability								$ 57,014	$ 627,792		$ 627,792
Debt instrument discount									53,333		53,333
Loss on derivative fair value measurement											3,681
Change in fair value of derivatives											651,427
Warrants issued | shares								100,000
Warrants [Member] | October 17, 2020 to October 23, 2020 [Member]
Derivative liability									$ 73,383		$ 73,383
Warrants issued | shares											187,000
Warrants [Member] | Measurement Input, Price Volatility [Member]
Derivative liability measurement input									1.10		1.10
Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative liability measurement input									0.0240		0.0240
Warrants [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Derivative liability measurement input | $ / shares									0.60		0.60
Warrants [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Derivative liability measurement input | $ / shares									0.80		0.80
Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Derivative liability measurement input term											10 months 14 days
Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Derivative liability measurement input term											11 months 26 days
Noteholder 8 [Member]
Derivative liability						$ 220,463	$ 220,463
Debt instrument face amount						$ 222,600	$ 222,600		$ 222,600		$ 222,600
Debt instrument maturity date						Nov. 15, 2019	Nov. 15, 2019				Nov. 15, 2019
Debt instrument discount						$ 184,957	$ 184,957		139,659		$ 139,659
Loss on derivative fair value measurement						$ 35,506
Noteholder 9 [Member]
Derivative liability					$ 98,091
Debt instrument face amount					$ 105,000				105,000		$ 105,000
Debt instrument maturity date					Dec. 27, 2019						Dec. 27, 2019
Debt instrument discount					$ 38,365				78,248		$ 78,248
Loss on derivative fair value measurement					$ 59,725
Noteholder 8 [Member]
Derivative liability			$ 322,521
Debt instrument face amount			$ 265,000						265,000		$ 265,000
Debt instrument maturity date			Feb. 4, 2020								Nov. 15, 2019
Debt instrument discount									224,168		$ 224,168
Loss on derivative fair value measurement			$ 322,521
Noteholder 9 [Member]
Derivative liability		$ 144,752
Debt instrument face amount		$ 131,250		$ 131,250					131,250		$ 131,250
Debt instrument maturity date		Feb. 5, 2020		Jan. 14, 2020							Dec. 27, 2019
Debt instrument discount		$ 14,423							111,832		$ 111,832
Loss on derivative fair value measurement		$ 130,329
Noteholder 9 [Member]
Derivative liability	$ 228,916
Debt instrument face amount	$ 131,250		$ 131,250						131,250		131,250
Debt instrument maturity date	Feb. 11, 2020		Feb. 4, 2020
Debt instrument discount									$ 113,990		$ 113,990
Loss on derivative fair value measurement	$ 228,916

Derivative Liability - Schedule

Derivative Liability - Schedule of Derivative Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Derivative Liability [Abstract]
Beginning, Balance			$ 1,181,278
Initial measurement of derivative liabilities			1,145,140
Change in fair market value	$ (1,409,305)	$ 1,780,769	(556,647)	$ 1,794,091
Write off due to conversion
Ending, Balance	$ 2,102,387		$ 2,102,387

Derivative Liability - Summary

Derivative Liability - Summary of Gain (Loss) on Derivative Liability (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Derivative Liability [Abstract]
Day one loss due to derivatives on convertible debt			$ (780,678)	$ (352,206)
Change in fair value of derivatives	$ (1,409,305)	$ 1,780,769	(556,647)	1,794,091
Total derivative gain (loss)			$ (556,647)	$ 1,794,091

Stock Options and Warrants (Det

Stock Options and Warrants (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock Options And Warrants
Stock option expense	$ 169,922	$ 72,587
Unrecognized stock-based compensation expense	$ 787,907

Stock Options and Warrants - Su

Stock Options and Warrants - Summary of Stock Option and Warrant Activity (Details)	6 Months Ended
	Mar. 31, 2019$ / sharesshares
Stock Options And Warrants
Beginning balance, Shares | shares	4,638,050
Granted, Shares | shares	646,920
Exercised, Shares | shares
Forfeited, Shares | shares
Expired, Shares | shares
Ending balance, Shares | shares	5,284,970
Weighted-Average Exercise Price Per Share, Beginning balance | $ / shares	$ 0.784
Weighted-Average Exercise Price Per Share, Granted | $ / shares	0.610
Weighted-Average Exercise Price Per Share, Exercised | $ / shares
Weighted-Average Exercise Price Per Share, Forfeited | $ / shares
Weighted-Average Exercise Price Per Share, Expired | $ / shares
Weighted-Average Exercise Price Per Share, Ending balance | $ / shares	$ 0.764

Stock Options and Warrants - Sc

Stock Options and Warrants - Schedule of Outstanding and Exercisable Options and Warrants (Details)	6 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of Option Shares, Outstanding | shares	5,284,970
Weighted Average Exercise Price, Outstanding | $ / shares	$ 0.783
Weighted Average Remaining Life (Years), Outstanding	2 years 9 months 25 days
Number of Option Shares, Exercisable | shares	4,513,720
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.764
Exercise Prices One [Member]
Number of Option Shares, Outstanding | shares	110,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 0.400
Weighted Average Remaining Life (Years), Outstanding	2 years 4 months 17 days
Number of Option Shares, Exercisable | shares	110,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.400
Exercise Prices Two [Member]
Number of Option Shares, Outstanding | shares	330,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 0.420
Weighted Average Remaining Life (Years), Outstanding	4 years 9 months 18 days
Number of Option Shares, Exercisable | shares	330,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.420
Exercise Prices Three [Member]
Number of Option Shares, Outstanding | shares	165,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 0.500
Weighted Average Remaining Life (Years), Outstanding	2 years 5 months 12 days
Number of Option Shares, Exercisable | shares	162,500
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.500
Exercise Prices Four [Member]
Number of Option Shares, Outstanding | shares	627,220
Weighted Average Exercise Price, Outstanding | $ / shares	$ 0.600
Weighted Average Remaining Life (Years), Outstanding	10 months 14 days
Number of Option Shares, Exercisable | shares	627,220
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.600
Exercise Prices Five [Member]
Number of Option Shares, Outstanding | shares	145,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 0.650
Weighted Average Remaining Life (Years), Outstanding	3 years 6 months 25 days
Number of Option Shares, Exercisable | shares	36,250
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.650
Exercise Prices Six [Member]
Number of Option Shares, Outstanding | shares	3,482,750
Weighted Average Exercise Price, Outstanding | $ / shares	$ 0.800
Weighted Average Remaining Life (Years), Outstanding	2 years 2 months 8 days
Number of Option Shares, Exercisable | shares	3,095,250
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.800
Exercise Prices Seven [Member]
Number of Option Shares, Outstanding | shares	100,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 0.850
Weighted Average Remaining Life (Years), Outstanding	4 years 18 days
Number of Option Shares, Exercisable | shares
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.850
Exercise Prices Eight [Member]
Number of Option Shares, Outstanding | shares	25,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 1.050
Weighted Average Remaining Life (Years), Outstanding	4 years 6 months 18 days
Number of Option Shares, Exercisable | shares
Weighted Average Exercise Price, Exercisable | $ / shares	$ 1.050
Exercise Prices Nine [Member]
Number of Option Shares, Outstanding | shares	220,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 1.260
Weighted Average Remaining Life (Years), Outstanding	3 years 2 months 30 days
Number of Option Shares, Exercisable | shares	110,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 1.260
Exercise Prices Ten [Member]
Number of Option Shares, Outstanding | shares	10,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 1.300
Weighted Average Remaining Life (Years), Outstanding	2 years 6 months 21 days
Number of Option Shares, Exercisable | shares	7,500
Weighted Average Exercise Price, Exercisable | $ / shares	$ 1.300
Exercise Prices Eleven [Member]
Number of Option Shares, Outstanding | shares	60,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 1.386
Weighted Average Remaining Life (Years), Outstanding	3 years 2 months 30 days
Number of Option Shares, Exercisable | shares	30,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 1.386
Exercise Price Twelve [Member]
Number of Option Shares, Outstanding | shares	10,000
Weighted Average Exercise Price, Outstanding | $ / shares	$ 1.666
Weighted Average Remaining Life (Years), Outstanding	3 years 4 months 2 days
Number of Option Shares, Exercisable | shares	5,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 1.666

Stock Options and Warrants - _2

Stock Options and Warrants - Schedule of Stock Option Granted Assumptions (Details)	6 Months Ended
	Mar. 31, 2019
Expected term of options granted	2 years
Expected dividend yield	0.00%
Minimum [Member]
Expected term of options granted	1 year 1 month 6 days
Expected volatility	102.63%
Risk-free interest rate	2.57%
Maximum [Member]
Expected term of options granted	5 years
Expected volatility	122.49%
Risk-free interest rate	2.67%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)

Aug. 30, 2019USD ($)TradingDays

Aug. 29, 2019USD ($)TradingDays

Aug. 08, 2019USD ($)TradingDays

Apr. 24, 2019USD ($)

Apr. 08, 2019USD ($)$ / sharesshares

Aug. 29, 2018USD ($)shares

Mar. 31, 2019USD ($)shares

Dec. 31, 2018USD ($)shares

Mar. 31, 2018USD ($)shares

Dec. 31, 2017USD ($)shares

Mar. 31, 2019USD ($)shares

Mar. 31, 2018USD ($)

Oct. 18, 2019USD ($)shares

Jun. 16, 2019USD ($)$ / sharesshares

Sep. 30, 2018USD ($)

Number of shares issued for services, value

$ 53,000

$ 128,400

$ 38,252

$ 241,157

Number of shares issued for conversion, value

$ 388,000

Debt instrument face amount

3,770,359

$ 3,770,359

$ 2,431,822

Proceeds from convertible debt

971,014

Finance lease

$ 1,294,845

1,294,845

Payment to financial lease

$ 93,050

$ 22,347

Firstfire Global Opportunities Fund LLC [Member]

Debt original principal amount

$ 220,000

Number of shares agree to issue | shares

1,000,000

Series D Preferred Stock [Member]

Number of shares issued for conversion | shares

Preferred stock issued upon conversion | shares

2.5

2.5

Number of shares issued for services | shares

Number of shares issued for services, value

Number of shares issued for conversion, value

Subsequent Event [Member]

Number of shares issued for services | shares

688,017

Number of shares issued for services, value

$ 192,390

Capital raised due to aggregate warrants

$ 586,000

Number of stock sold | shares

1,465,000

Sale of stock price per share | $ / shares

$ 0.40

Warrant exercise price | $ / shares

$ 0.65

Debt instrument conversion price per share | $ / shares

$ 0.40

Lease term

30 months

Finance lease

$ 467,837

Payment to financial lease

67,459

Subsequent Event [Member] | 30 Payments [Member]

Payment to financial lease

$ 18,226

Subsequent Event [Member] | Convertible Notes Payable One [Member] | Unrelated Party [Member]

Debt instrument face amount

$ 33,092

Proceeds from convertible debt

$ 31,517

Debt instrument interest rate

8.00%

Debt instrument maturity date

Aug. 8, 2020

Debt instrument trading days percentage

35.00%

Debt instrument convertible trading days | TradingDays

15

Subsequent Event [Member] | Convertible Notes Payable One [Member] | Third Party [Member]

Debt instrument face amount

$ 1,575

Subsequent Event [Member] | Convertible Notes Payable Two [Member] | Unrelated Party [Member]

Debt instrument face amount

33,092

Proceeds from convertible debt

$ 31,517

Debt instrument interest rate

8.00%

Debt instrument maturity date

Aug. 8, 2020

Debt instrument trading days percentage

35.00%

Debt instrument convertible trading days | TradingDays

15

Subsequent Event [Member] | Convertible Notes Payable Two [Member] | Third Party [Member]

Debt instrument face amount

$ 1,575

Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Party [Member]

Debt instrument face amount

$ 110,000

Proceeds from convertible debt

$ 100,000

Debt instrument interest rate

8.00%

Debt instrument maturity date

May 30, 2020

Debt instrument trading days percentage

35.00%

Debt instrument convertible trading days | TradingDays

15

Original issue discount

$ 10,000

Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Party [Member] | Exchange Agreement [Member]

Debt instrument face amount

$ 199,203

Debt instrument interest rate

8.00%

Debt instrument maturity date

May 29, 2020

Debt instrument trading days percentage

35.00%

Debt instrument convertible trading days | TradingDays

15

Subsequent Event [Member] | Debenture Holder [Member]

Debt instrument conversion price per share | $ / shares

$ 0.60

Outstanding debentures

$ 5,183,000

Outstanding debentures opted for the offer

4,654,000

Outstanding debentures yet to accept the offer

$ 529,000

Additional shares to be issued related to accepted offers | shares

3,878,333

Subsequent Event [Member] | Officers and Directors [Member]

Number of restricted stock grants | shares

12,500

Number of restricted stock grants, value

$ 6,624

Subsequent Event [Member] | Accounts Payable [Member]

Common shares issued for settlement of debt | shares

58,245

Common shares issued for settlement of debt, value

$ 21,000

Subsequent Event [Member] | Convertible Notes Payable [Member]

Number of shares issued for conversion | shares

1,201,420

Common shares issued for settlement of debt | shares

381,351

Common shares issued for settlement of debt, value

$ 165,000

Number of shares issued for conversion, value

$ 357,222

Subsequent Event [Member] | Series D Preferred Stock [Member]

Number of shares issued for conversion | shares

25,000

Preferred stock issued upon conversion | shares

10,000